



## Doctors' understanding of individualisation of drug treatments: A qualitative interview study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002706
Article Type:	Research
Date Submitted by the Author:	08-Feb-2013
Complete List of Authors:	Denford, Sarah; University of Exeter Medical School, Health Services Research Frost, Julia; University of Exeter Medical School, Health Services Research Dieppe, Paul; University of Exeter Medical School, Health Services Research Britten, Nicky; University of Exeter Medical School, Health Services Research
<b>Primary Subject Heading</b>:	Health services research
Secondary Subject Heading:	Qualitative research
Keywords:	PRIMARY CARE, QUALITATIVE RESEARCH, SOCIAL MEDICINE

SCHOLARONE™  
Manuscripts

1  
2  
3 **Doctors' understanding of individualisation of drug treatments: A qualitative interview**  
4 **study**  
5  
6

7 S Denford<sup>1</sup>, J Frost<sup>1</sup>, P Dieppe<sup>1</sup>, N Britten<sup>1</sup>  
8

9 <sup>1</sup>University of Exeter Medical School, institute of Health Services Research, Exeter, UK  
10  
11

12  
13  
14 Correspondence to:

15 Sarah Denford

16  
17 University of Exeter Medical School,  
18

19 Veysey Building,  
20

21 Salmon Pool Lane,  
22

23 Exeter, EX2 4SG  
24

25 [Sarah.denford@pms.ac.uk](mailto:Sarah.denford@pms.ac.uk)  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 Key words: Individualisation, drug treatment, self-management, chronic conditions, qualitative.  
56

57 Total word count: 4860 (abstract: 188)  
58  
59  
60

## ABSTRACT

### Objective

To explore doctors' understanding of individualisation of drug treatments, and identify the methods used to achieve individualisation.

### Design

In this exploratory study, we used in-depth qualitative interviews with doctors to gain insight into their understanding of the term 'individualised treatments' and the methods that they use to achieve individualised treatments.

### Participants

Sixteen General Practitioners (GPs) in six rural and 10 urban practices and four hospital consultants were recruited.

### Setting

Doctors from primary and secondary care in South West of England.

### Results

Understanding of individualisation varied between doctors, and initial descriptions of individualisation were not always consistent with examples given. Understandings of, and methods used to achieve individualised treatment were frequently discussed in relation to making drug treatment decisions. Few doctors spoke of using tools to support patients to individualise their own treatments after the consultation.

### Conclusion

Despite its widespread use, variation in doctors' understanding of the term individualisation highlights the need for it to be defined. Efforts are needed to develop effective tools to support patients to manage their treatments after consultations. Such a tool would offer a structured approach to support patients to self-manage their condition.

## ARTICLE SUMMARY

### Article focus

- To explore doctors' understanding of individualisation of drug treatments
- To identify the methods used to achieve individualisation

### Key messages

- There is a lack of consensus about whether individualised treatments are doctor-led, evidence based treatments, or treatments that are prescribed after consideration of patients' priorities.
- Doctors' stated definitions of individualisation were not always congruent with the examples they provided.
- Doctors rarely referred to patients' use of their medication after the consultation.

### Strengths and limitations

- The use of qualitative methods generated a rich insight into doctors' understanding of individualisation, methods used to achieve individualisation, and the relationships between the two
- Strategies were used to enhance the trustworthiness of the data including multiple coders, respondent validation and triangulation of findings with the existing literature
- However, use of opportunity sampling may have resulted in a self-selected sample

## INTRODUCTION

Self-management is the foundation of chronic disease management. However, self-management is not straight forward. Policy initiatives advocate that treatments are tailored, personalised or individualised to patients' needs<sup>[1]</sup> and that patients are supported to self-manage their conditions<sup>[2]</sup>. However, terms such as individualisation and personalisation are regularly used to refer to a number of things<sup>[3]</sup>. It is often unclear as to whether individualised treatments are individualised to patients' medical needs or their personal needs<sup>[3]</sup>; which may or may not be complementary.

Successful pharmacological management of disease requires appropriate drug prescribing by doctors and appropriate drug utilisation by patients. This involves (at least) three processes. First is the interaction between the doctor and the patient within the medical consultation. The task here is to make a correct diagnosis and select appropriate treatments. Next is the doctor's prescription of appropriate drugs to treat the individual patient if necessary. The third process is the patient's use of the drug in the context of their lives. This process is not linear; interactions between doctors and patients will occur both before and after the prescription has been written and further interactions between patients and doctors are likely to occur during follow-up consultations. Treatments may be individualised at any stage.

Evidence based guidelines are available to support doctors to select appropriate drugs for individual patients. However, there remains a degree of uncertainty regarding the effectiveness of certain pharmacological treatments for individual patients<sup>[4]</sup>. Results of randomised controlled trials cannot always be accurately applied to individual patients<sup>[5,6]</sup>. Individual variation in the severity of the condition, presence of co-morbidity, genetic profile, polypharmacy, and psychosocial factors all influence the effectiveness of the treatment and the potential risk of adverse drug reactions<sup>[5]</sup>. For individuals with multiple conditions, on multiple medications, or with a new or rare condition, guidelines are often unsuitable or unavailable<sup>[7]</sup>. A large body of research promotes models of interaction or decision making such as patient centred care<sup>[8]</sup> and shared decision making<sup>[9]</sup>. These are recommended by academics and policy makers as potential solutions in which patients' views and priorities are explored and treatment decisions are negotiated<sup>[1,11]</sup>. Despite recommendations, these 'solutions' are not routinely used in clinical practice<sup>[11,12]</sup>, and there is very little consensus about what these terms entail or how they should be implemented<sup>[12-14]</sup>.

1  
2  
3 Previous qualitative research has explored how healthcare providers make individualised  
4 treatment decisions in the face of competing priorities<sup>[15-17]</sup>. That research highlights the  
5 variation in the strategies doctors employ to make treatment decisions in such situations<sup>[15,</sup>  
6  
7  
8 <sup>17]</sup>. Doctors vary in their use of evidence and how they resolve the tensions that are  
9 inherent in using evidence alone (i.e., without consideration of patients' preferences).  
10  
11 When faced with complex patients, doctors approach decisions with caution and  
12 uncertainty<sup>[17-19]</sup>.  
13

14  
15 Should a drug be prescribed, the third process is the patients' use of the drug after the  
16 consultation. In a synthesis of qualitative studies of medication taking, Pound et al found  
17 that patients' use of medication is influenced by their judgements about the relative risks  
18 and benefits of using medications, the likelihood and impact of adverse effects, and the  
19 acceptability of the treatment regime in their lives<sup>[20]</sup>. Pound et al found evidence to  
20 suggest that patients are often motivated to minimise their use of medication - to reduce  
21 the dose of medication whilst still achieving some gain or to make the regime more  
22 acceptable or cost effective<sup>[20]</sup>. Patients actively sought answers to questions they had  
23 about their medication, for example, by modifying their treatment regimes by stopping or  
24 lowering the dose of medication to test its effectiveness (lay testing); only taking  
25 medication when symptomatic (symptomatic use of medication); only taking medication or  
26 taking more medication to offset lifestyle factors such as drinking alcohol (strategic use of  
27 medication) and replacement of medication with non pharmacological treatments. Thus,  
28 many patients carry out their own individualisation according to their own criteria.  
29  
30  
31  
32  
33  
34  
35  
36

37  
38 This project aims to explore doctors' understanding of the term 'individualised treatments' and the  
39 methods that they employ to achieve individualised treatments.  
40

## 41 **METHODS**

### 42 **Design**

43  
44 In this exploratory study, we used in-depth qualitative interviews<sup>[21]</sup> with doctors to explore their  
45 understanding and clinical practice.  
46  
47  
48

### 49 **Sampling and data collection**

50  
51 We used opportunity sampling to recruit doctors to the study. We emailed information about the  
52 study to practices on the Devon Primary Care Incentive Scheme register, and asked interested  
53 doctors to make contact and arrange a time and place for the interview to take place.  
54  
55  
56  
57  
58  
59  
60

Our topic guide was based on a review of the literature and our own clinical experience. We used open ended questions to explore doctors' understanding of individualisation and the methods or strategies that they employ to deal with situations that require individualised treatment. In order to obtain detailed accounts, doctors were encouraged to provide examples whenever possible. All participants provided written consent prior to taking part.

Ethical approval was obtained from the Peninsula College of Medicine and Dentistry ethics committee.

### **Data analysis**

Interviews were audio recorded, anonymised and transcribed verbatim. We analysed the data using a thematic approach<sup>[22]</sup>. Two researchers independently read transcripts and noted down core themes that were identified. We met regularly to discuss themes and to develop a preliminary list of codes. As coding progressed, we drew on the existing literature to refine this list and to group related themes together<sup>[23]</sup>.

We then developed a chart for each theme<sup>[23]</sup>, and copied any interview data that was related to each theme into the relevant chart. To enhance rigour<sup>[24]</sup>, two authors carried out this process independently. We resolved discrepancies via discussion<sup>[25]</sup>. We then used the charts to identify narratives within cases and diversity between cases<sup>[26]</sup>. Divergent cases were discussed and included in the thematic analysis<sup>[26]</sup>.

A summary of the findings were sent to all doctors along with an invitation to offer any comments.

## **RESULTS**

One author collected data between February and July 2012 from sixteen General Practitioners (GPs) (six rural and ten urban practices) and four hospital consultants from clinical practices in Devon. Seven doctors were female. Interviews were held at a location to suit the doctors (mainly the doctor's place of work). Interviews lasted between twenty and sixty minutes.

The data are presented under two main headings. Firstly we identified two sub-themes relating to doctors' understanding: evidence based medicine and doctor-led prescribing, and individualising treatments around patient factors. Secondly we identified two sub-themes under the heading methods used to individualise treatments: methods used to make treatment decisions during the consultation, and methods to support patients after the consultation.

### **Understanding of individualised treatment**

1  
2  
3 Doctors' understanding of individualisation ranged from evidence based, medically focused, doctor-  
4 led care to prescribing drug treatments tailored to the patients' wishes. Whilst all but two doctors  
5 were able to describe their understanding of individualisation when asked, these answers did not  
6 always match the examples they provided. Doctors frequently discussed individualisation in relation  
7 to two of the processes involved in the prescription and use of pharmacological treatment - selecting  
8 appropriate drugs to treat the individual patient, and the interaction with the patient in the medical  
9 consultation. Doctors paid less attention to patients' use of treatments post consultation.  
10

#### 14 Evidence based medicine and doctor-led prescribing

15  
16 At one end of the spectrum, individualisation was considered to be synonymous with evidence  
17 based practice. Focussing on the doctors' task of selecting appropriate drugs to treat the individual  
18 patient, one doctor described how the process of matching patients with guidelines resulted in all  
19 treatments being individualised:  
20  
21

22  
23  
24 "I suppose when I did discuss it recently with my colleague the point he made was all  
25 treatments are individualised and it's, perhaps you're looking at it from a different  
26 perspective, because we look at it from the individual that comes in and then try and match  
27 a guideline to them or guidance, so everything you do is individualised anyway." (014)  
28  
29

30  
31 Importantly, when asked about their understanding of individualised treatment, no doctor referred  
32 to doctor-led prescribing specifically. However, it was implicit in their examples that in certain  
33 situations (i.e., if the doctor thought that the patient really could benefit from treatment), they  
34 considered a doctor-led style of prescribing to be individualised.  
35  
36

37  
38 "Well again, it's a case of looking at what is right for that particular patient at that particular  
39 time, and, I, I, because the patient was at high risk of stroke, then I did really try to push the  
40 treatment." (004)  
41  
42

43  
44 "You know, because I think if, somebody might be very against a drug, but if I've  
45 seen it work really effectively in the past, I suppose I feel, I wouldn't force them to  
46 take it, if I force them to take it they won't take it anyway, but I suppose I feel if I  
47 can find a way round it that would encourage them just to give it a go, sometimes  
48 it's worth it." (019)  
49  
50

#### 51 Individualising treatments around patient factors

52  
53 Doctors described individualised treatments as drug treatments that had been selected after  
54 consideration of patient factors (such as patient circumstances). Frequently, this meant adapting or  
55 going against guideline recommendations. Some doctors described individualised treatments as  
56  
57  
58  
59  
60



1  
2  
3 treatments that had been tailored to suit the patients' medical needs (e.g., when treating patients  
4 with co-morbidities):

5  
6 "Well it's always checking on individual preferences, but the biggest factor is co-  
7 morbidity, that's what makes me step outside the box as it were." (012)  
8  
9

10 For other doctors, individualised treatments were treatments that had been adapted to  
11 suit patients' social circumstances:

12  
13  
14 "So, I've got someone who lives out the back of beyond, no transport, they might  
15 be less keen to have something that requires frequent monitoring... We have a lot  
16 of shift workers round here so that can be quite an issue, um, shifts will often  
17 change from week to week... complete nightmare controlling anything like that  
18 because they're sometimes asleep when they're supposed to be taking their pills.  
19 So they can be tricky." (017)  
20  
21  
22  
23

24 For some, individualised treatment required the patient to be involved in treatment decisions; with  
25 treatments being individualised around what the patient is prepared to do. These doctors  
26 considered patients' preferences to be more important than their own views and preferences. In  
27 particular, the two geriatricians in our sample were conscious that the patients' preferences are  
28 perhaps more important than achieving optimal control of their conditions:  
29  
30  
31

32  
33 "Because most of the patients that we see have reached what statistically would  
34 be regarded as their life expectancy. So there is, we can't in anyway force our  
35 opinions on them. We have to go with the fact that they have made this value  
36 judgement as to what is the right thing for them... And we just have to accept that  
37 they've made the right judgement for them. Which is not necessarily the right  
38 judgement for us. But as long as we feel that they are fully informed, or as  
39 informed as they can be, then we just accept what decisions they make on their  
40 behalf." (001)  
41  
42  
43  
44  
45

46 "Maybe that's easier in geriatrics where we know lots of what we do comes at a  
47 price, we know 10% of hospital admissions that we do are from drug side effects.  
48 So maybe we feel a bit more relaxed about it." (013)  
49  
50

51 For others, individualising treatment in accordance with what the patient was prepared to  
52 do simply meant accepting that the patient had declined treatment:

53  
54  
55 "And I'm quite happy to agree to differ, if they want to decline treatment, I'd write  
56 down declined treatment. I think it's important to come back to, not just see it as  
57  
58  
59  
60

1  
2  
3 something that they've done wrong, but it's fine for them to do that, and I don't  
4 have a problem with them not taking that treatment." (006)  
5  
6

### 7 **Methods used to individualise treatments**

8  
9 Doctors described the methods they used to achieve individualisation. Again, doctors focused on the  
10 methods used to select appropriate drugs to treat individuals and interactions with the patients  
11 during the consultation. Few doctors spoke of methods to support the patient to use treatments  
12 after the consultation when drug taking actually occurs.  
13  
14

15  
16 **Methods used to make treatment decisions during the consultation**

17  
18 Doctors described using a range of resources to select appropriate drugs to treat individual patients.  
19 These included evidence, clinical experience, colleague support, and the patients' views or  
20 circumstance. Use of resources was dependent on doctors' understanding of individualisation, but  
21 influenced by the patient and the situation. All doctors described using evidence to make treatment  
22 decisions. However, views about the role of the evidence varied between doctors:  
23  
24  
25

26 "EBM is only one of many strategies, and, it's like you've got a tool box you know? And the  
27 tool that you use every time is you yourself. And you need, and you can learn to do that  
28 better. I'm very interested in that. And then occasionally you'll pull EBM out as well. But not,  
29 you know, not very often. Honestly, I would think I probably, as a first tool that you pull out,  
30 it would probably be once or twice a day." (010)  
31  
32  
33  
34

35 It was widely acknowledged that text book scenarios were rare. One general practitioner reported  
36 that most of his patients had complex social needs, and both the geriatricians in our sample  
37 reported that nearly all of their patients had multiple conditions. These complex patients could not  
38 be treated only using evidence based guidelines<sup>[7]</sup>. Treatment decisions for patients with complex  
39 needs were made based on their own or their colleagues' clinical experience:  
40  
41  
42

43 "Often we send messages to each other. I share a list with another GP colleague,  
44 and we share difficult patients, and discuss how are we going to get Mr so and so  
45 to do X, Y and Z?" (014)  
46  
47  
48

49 To treat patients with complex needs, doctors often made treatment decisions for the patient, using  
50 strategies like polypharmacy to deal with side-effects of treatments, and accepting that not all  
51 conditions can be optimally managed:  
52  
53

54 "Q: Ok, so when you've got a patient who comes in and has a range of medical conditions,  
55 and you know if you treat all of them it's going to lead to interactions?  
56  
57  
58  
59  
60

1  
2  
3 A: The regimens for each of these conditions, A, B and C are reasonably well sorted because  
4 they're common conditions, common drugs, usually sorted. So he has arthritis, diabetes and  
5 epilepsy. That's a nice juicy mix, and fairly common. By and large you will get away with this  
6 polypharmacy." (008)  
7  
8

9  
10 To involve the patient in the treatment decisions, doctors reported using techniques such as  
11 providing the patient with the information needed to make an informed choice, suggesting  
12 treatment and outcome options, and giving the patient time to think about their priorities:  
13

14  
15 "And then we can provide them with alternatives like 'well this will cure that but  
16 this could affect your kidneys. This might not have as big an effect on that but it  
17 would preserve the kidneys and could leave you a little bit short of breath. Of  
18 those two which would you rather have? The risk of feeling completely healthy,  
19 but potentially shorter life, or having some symptoms but a longer life?' And  
20 working with those decisions." (001)  
21  
22  
23  
24

25 Whilst one doctor aimed to prescribe treatments in accordance with patients' interests, he  
26 accepted that this could not be an everyday occurrence:  
27

28  
29 "I'll be honest; I don't do it all the time, so I don't want to pretend I'm perfect at  
30 this. I think the clearest one that I've got is a bloke in his late 50s with Parkinsons  
31 who'd retired, but the thing that kept him going was that he could go to the  
32 swimming pool every morning... So we opted for a patch for him... You slap it on  
33 once a day and it gives you 24 hour coverage so he could put it on the night  
34 before and he'd be switched on in the morning, he wasn't waiting for a tablet to  
35 kick in and make him work. And it worked beautifully for him... but after a few  
36 months he got skin reactions and we had to stop it and find something else, but  
37 that really felt like we had really picked a drug around him and his interests and  
38 what was keeping him going." (013)  
39  
40  
41  
42  
43  
44  
45

46 Interviewees also reported situations in which a more directive approach was considered to  
47 be necessary. This included situations in which patients' goals were deemed unrealistic, or  
48 when the doctor thought that the patient really should be using some form of treatment. In  
49 such situations, doctors reported using techniques in order to convince or persuade the  
50 patient to follow recommendations. In some cases, attempts were made to encourage the  
51 patient to see the medical imperative for treatment:  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 “They don't want to take any tablets, you say ‘well you probably will die in 5 years time at  
4 the most without these things. If you take these things it might prolong your life, by this that  
5 or the other.’” (007)  
6  
7

8 For some doctors, the assumption appeared to be that the patient was in some way misinformed.

9  
10 Therefore, attempts were made to educate the patient:

11  
12 “Most of the time you can explain to people why they ought to be taking  
13 something and hopefully they might come round to thinking that that’s the best  
14 thing to do. Sometimes people might have different ideas and won’t take anything  
15 or certainly won’t take what you suggest but I think most of the time you can  
16 explain to people why or what the evidence is or what the consensus is. And most  
17 of the time if people understand it they’ll take it.” (022)  
18  
19  
20  
21

22 If initial treatment decisions were not acceptable to the patient, attempts were made to  
23 change or simplify the regime or to prescribe alternative treatments:

24  
25 “You just say ‘well let’s try something else.’ The nice thing is, there’s always, or very  
26 often there’s always alternatives that are either as good or, uh, you know, in the  
27 same league.” (014)  
28  
29  
30

31 Methods used to support patients after the consultation

32  
33 In most interviews, individualisation was described in the context of making treatment  
34 decisions during the consultation. Few doctors spoke of methods to support patients to test  
35 and refine their treatment in the context of their own life. To support patients after the  
36 consultation, doctors reported using techniques such as reminders and instructions. This  
37 ranged from standardised dosette boxes or text messaging services, to writings and  
38 drawings on prescription labels. Crucially, the aim of such strategies was to help the patient  
39 use their medications as prescribed:  
40  
41  
42  
43  
44

45 “Q: Do you use any strategies to support the patients outside the consultation?

46  
47 A: Um, not enough. It’s something I often think about that I should be doing more.  
48 So I do drawings and write things on bits of scrap paper, about if there is a  
49 complicated medication, or a list of things to do, or if people are older, forgetful”  
50  
51  
52 (006)  
53

54 A minority of doctors described using strategies to help patients modify treatment regimes  
55 to suit their lives. One geriatrician described how he used techniques such as separating  
56  
57  
58  
59  
60

1  
2  
3 drugs into those that have to be taken (to treat the condition) and those that do not have  
4 to be taken (to treat the symptoms):  
5

6  
7 “I tend to rearrange them so into treatments and symptoms... And if you group  
8 them like that, then if they get half way through the tablets, providing they’ve  
9 taken their treatment tablets, the symptom control, if they don't take it they’re  
10 going to feel lousy, but the balance between taking a tablet or not taking a tablet,  
11 it’s not going to make any difference to their longer term health.” (001)  
12  
13

14  
15 Another geriatrician described a process of trial and error, in which drugs were used for a  
16 period of time and then modified by the doctor if necessary:  
17

18  
19 “I think as well, because we tell patients for a lot of these drugs let’s try this and  
20 see if it works, if it’s not working we’ll stop it. It allows patients to come back and  
21 say it’s not working rather than come back and feel that they’re on it.” (013)  
22  
23

24  
25 Only one general practitioner actively encouraged patients to modify their treatments to  
26 achieve individualised doses. This doctor described reluctance on behalf of some patients  
27 to do so:  
28

29  
30 “So actually, for an awful lot of drugs, I do this all the time. I say balance up your,  
31 you know yourself when you’re getting the side effects. Titrate the medication until  
32 you’re just below the level at which you get the side effects and fiddle around with  
33 it... And then sometimes the patient’s say, ‘ohh, but it says once a day and bla bla  
34 bla.’” (007)  
35  
36  
37

38  
39 The hospital consultants in our sample reported used diaries and graph paper to either  
40 assess the effectiveness of treatments and treatment doses, or to encourage patients to  
41 respond to worsening symptoms:  
42

43  
44 “So, it’s just a piece of paper really with days of the week and what their Parkinsons  
45 is like. But Parkinsons you swing from being on, when you can move around, to  
46 being off, when you’re frozen and stuck. So if we’re trying to give a drug to reduce  
47 the amount of time people are off , we’ll often give them a diary so you can  
48 graphically see whether it’s worked or not.” (013)  
49  
50

51  
52 “Well they all get the graph paper. And it’s “If it goes above this line, phone us and  
53 we’ll see you in clinic straight away. Or, if it goes above this line increase your  
54 tablets. Or do this that or the other.” And it’s what we tell them to do when it  
55 reaches that point that varies by patients.” (001)  
56  
57  
58  
59  
60

1  
2  
3 The question of whether or not patients needed to be encouraged to monitor symptoms  
4 was contested. Some doctors were of the opinion that patients should not be encouraged  
5 to monitor their symptoms or side-effects of their treatments:  
6  
7

8 "I quite often don't tell people about the side effects of tablets, which is against  
9 our, against all the modern day teachings that you must tell people of the risks.  
10 Well I often don't. Because there's a lot of evidence for this, there's a type of  
11 patient that if you tell them there is a possibility that they'll get headaches, they'll  
12 get headaches." (002)  
13  
14  
15

16  
17 Others felt that patients should be told what potential side effects they should look out for:

18 "Explain to them the possibility that one thing might affect another and what to  
19 look out for. So if there are going to be interactions, what they, what they need to  
20 be um, coming back with um, if certain symptoms present. You know if you get this,  
21 come back, because that's a side effect we need to know about." (016)  
22  
23  
24  
25

26 However, even with clear instructions, mistakes could happen:

27 "We've had that with a patient who used, you know, he had the line [indicating safe  
28 blood pressure readings], he went way below the line, kept on going without  
29 bothering to phone anyone, and six weeks later he was in hospital with renal  
30 failure. And we gave him pretty clear instructions. He decided to ignore them... It  
31 worked; he just didn't follow the instructions. But you can't do anything about that.  
32 Patients are entitled to do what they want." (001)  
33  
34  
35  
36  
37

38 There was wide acceptance that, in the end, the final treatment decision was down to the  
39 patient. In certain situations, no treatment could be the best option:

40 "You know, you say, 'this is what's going on, you tried them we've looked at  
41 physiotherapy, we've looked at other alternatives, are your symptoms  
42 manageable? Are the treatments worse than the condition, and if they are, then  
43 maybe you need to learn to live with the condition.'" (017)  
44  
45  
46  
47  
48

## 49 DISCUSSION

### 50 Main findings and comparisons with other studies

51 This paper presents a range of understandings of the meaning of individualised drug treatment.  
52 Overall, there was a lack of consensus about whether individualised treatment was treatment that  
53 was tailored to patients' priorities or treatment that was doctor-led, and followed evidence based  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 guidelines. Furthermore, there was a lack of congruence between doctors' stated definition of  
4 individualisation and the examples they provided. Doctors frequently spoke of methods to support  
5 interactions during consultations, the first of the processes referred to in the introduction of this  
6 paper. However, despite the findings of Pound et al<sup>[20]</sup>, doctors in our study infrequently mentioned  
7 patients' use of their medications outside the consultations.  
8  
9

10  
11 The main strength of this study is the use of qualitative methods to generate a rich insight into  
12 doctors' understanding of individualisation, methods used to achieve individualisation, and the  
13 relationships between the two. We used strategies to enhance the trustworthiness of our study,  
14 including multiple coders and respondent validation. We triangulated our findings with the existing  
15 literature, and asked participants to comment on our findings<sup>[28]</sup>. Our study was based on a sample  
16 of hospital consultants and general practitioners from the South West of England. That doctors were  
17 only recruited from this area could limit the transferability of the results, although participants had  
18 both trained and practised beyond this region. Whilst we report that the four hospital consultants  
19 appeared to be more willing than general practitioners to individualise treatments after the  
20 consultation, this is based on a small number of participants. Further research is needed to explore  
21 differences in individualisation between different clinical areas as this may highlight situations  
22 clinical areas in which individualisation is commonly achieved, and situations in which  
23 individualisation is not appropriate. We acknowledge that our use of opportunity sampling may  
24 have resulted in a self-selected sample. However, our results demonstrate the lack of consensus  
25 about what individualisation of drug treatments means to participating doctors, suggesting that  
26 there is no shared understanding of what the term means. The lack of consistency between  
27 respondents' definitions of individualisation and the examples they gave suggests that there may  
28 also be inconsistency between their explanations and their clinical practice.  
29  
30

31 Previous qualitative research has explored methods to support doctors during consultations<sup>[15-17]</sup>. In  
32 those studies, the focus was on strategies used by doctors to make individualised prescribing  
33 decisions within the medical consultation - where guidelines may not be appropriate. Similar to the  
34 doctors in our study, those in the study by Fried et al. had variable views about how treatment  
35 decisions for patients with complex conditions should be made. Use of evidence and strategies to  
36 balance the harms versus the benefits of guideline directed care varied between physicians. Doctors  
37 in both studies had differences of opinion regarding the role of the patient in treatment decisions.  
38 For some, treatment decisions should be doctor-led, with the doctor persuading the patient to use  
39 the treatment that they thought would be most appropriate. For others, patient involvement was an  
40 essential component of treatment decisions. A number of doctors reported that integrating patients'  
41 preferences into medical decisions was problematic if the treatment was essential. This was still a  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 major concern for many doctors, despite research suggesting that patients' and doctors' priorities  
4 may be very different<sup>[27]</sup>. Pound et al found evidence to suggest that patients actively modify their  
5 medications in order to suit their lives<sup>[20]</sup>. However, there is a paucity of literature surrounding  
6 methods used to support patients during this third process. The few doctors in our study who spoke  
7 of methods to support patients outside the consultation described methods such as sorting drugs by  
8 their role (to treat or to cure), trial and error, and monitoring. These strategies are largely informal:  
9 drawings, or writings about the use of the medication on bits of paper. The limitations of such  
10 informal methods were acknowledged.

11  
12 Our study highlights the variation in opinions about whether or not patients should be encouraged  
13 to adapt treatments after consultations. One doctor felt that patients did not want to adapt their  
14 treatments. Another doctor thought that encouraging patients to be aware of side-effects could  
15 actually contribute to side effects. Others were concerned that encouraging patients to monitor  
16 symptoms could lead to unnecessary stress. Only a small number of doctors (mainly from secondary  
17 care) thought that patients should be encouraged to individualise treatments after the consultation.  
18 However, as Pound et al., (2005) has shown, many patients will monitor their symptoms and side  
19 effects and make treatment adaptations as necessary – with or without the support of the doctor.  
20 Self-management of chronic disease requires patients to take multiple treatments and monitor their  
21 health over many years. Developing tools to support patients to modify treatments, and providing  
22 safe parameters for them to do so, may actually limit dangerous adaptations.

23  
24 The findings reported here have important implications for research and practice. The focus of the  
25 doctors in this study was on the strategies and methods that they used to reach decisions within the  
26 consultation. Few doctors discussed methods to support patients to use drug treatments outside the  
27 consultation. Methods that were suggested were informal and unstructured, and doctors  
28 acknowledged that such methods may neither be supportive enough or measurable. Furthermore,  
29 doctors perceived a number of barriers to individualising treatments after the consultation; such as  
30 whether or not strategies could contribute to side-effects and cause unnecessary stress. Before  
31 policy recommendations concerning both individualisation and self-management can be achieved  
32 commissioners need to be clear about what they are advocating, thus, the concept of  
33 individualisation needs to be refined. Methods used to achieve individualisation may then be  
34 developed and piloted in different situations. Such methods should be appropriately structured to  
35 be supportive and their effects measurable. Given that some patients are already individualising  
36 treatments on their own, supporting patients to do so safely could improve patients' self-  
37 management practices.



### Acknowledgements

We would like to thank the participants who took part in the research.

### Competing interests

All authors have completed the ICMJE uniform disclosure at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare: SD's time is funded by NIHR; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced this work.

### Funding

This article presents independent research funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for the South West Peninsula. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health in England

### Copyright

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide license to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) license any third party to do any or all of the above.

### Contributions and guarantor

All four authors had a substantial contribution to the conception and design of the research. The analysis and interpretation of the data was undertaken by Sarah Denford, with considerable input from Julia Frost, Nicky Britten and Paul Dieppe. The article was drafted by Sarah Denford, and revised by the remaining three authors. All four authors approved the final version of the article before publication. There were no other contributors that are not included as an author. Sarah Denford is the guarantor.

### Data sharing

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Full dataset is available from the corresponding author at Sarah.denford@pms.ac.uk. Consent was not obtained but the presented data are anonymised and risk of identification is low.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2013-002706 on 17 May 2013. Downloaded from <http://bmjopen.bmj.com/> on May 30, 2023 by guest. Protected by copyright.

## REFERENCE LIST

- (1) Department of Health. Equity and excellence: Liberating the NHS. Stationary Office, 2010.
- (2) Department of Health. Supporting people with long term conditions. Stationary Office, 2005.
- (3) Cribb A, Owens J. Whatever suits you: unpicking personalization for the NHS. *J Eval Clin Pract* 2010;16(2):310-4.
- (4) Evans I, Thornton H, Chalmers I, et al. Testing treatments better research for better healthcare. London: Pinter & Martin, 2010.
- (5) Kravitz RL, Duan N, Braslow J. Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages. *Mil Quart* 2004;82(4):661-87.
- (6) Mant D. Can randomised trials inform clinical decisions about individual patients? *Lancet* 1999;353(9154):743-6.
- (7) Boyd CM, Darer J, Boulton C, et al. Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid Diseases. *JAMA* 2010;294(6):716-24.
- (8) Lewin S, Skea Z, Entwistle VA, et al. Interventions for providers to promote a patient-centred approach in clinical consultations (Cochrane review). *Cochrane Libr* 2012; 2001;(4):CD003267.
- (9) Marshall M, Bibby J. Supporting patients to make the best decisions. *BMJ* 2011;342:d2117.
- (10) Department of Health. Government response to the NHS future forum report. Norwich; 2011.
- (11) Agedahl KM, Gulbrandsen P, Forde R, et al. Courteous but not curious: how doctors' politeness masks their existential neglect. A qualitative study of video-recorded patient consultations. *J Med Ethics* 2011;(24)107-113.
- (12) Richards N, Coulter A. Is the NHS Becoming more Patient-centred? Trends from the National Surveys of NHS Patients in England 2002-07. London: Picker Institute; 2007.
- (13) Cribb A, Entwistle VA. Shared decision making: trade-offs between narrower and broader conceptions. *Health Expect* 2011;14(2):210-9.
- (14) Sandman L, Munthe C. Shared decision making, paternalism and patient choice. *Health Care Anal* 2010;18(1):60-84.
- (15) Fried T, Tinetti ME, Iannone L. Primary Care Clinicians' Experiences With Treatment Decision Making for Older Persons With Multiple Conditions. *Arch Intern Med* 2011;171(1):75-80.
- (16) Luijckx HD, Loeffen MJ, Lagro-Janssen AL, et al. GPs' considerations in multimorbidity management: a qualitative study. *Br J Gen Pract* 2012;62:e503-e510.
- (17) Anderson N, Fuller R, Dudley N. 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. *QJM* 2007;100(5):263-9.

- 1  
2  
3 (18) Schattner A, Fletcher RH. Research evidence and the individual patient. QJM 2003;96(1):1-5.  
4  
5 (19) Griffiths F, Green E, Tsouroufli M. The nature of medical evidence and its inherent  
6 uncertainty for the clinical consultation: qualitative study. BMJ 2005;330(7490):511.  
7  
8 (20) Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of  
9 medicine taking. Soc Sci Med 2005;61(1):133-55.  
10  
11 (21) Britten N. Qualitative interviews in medical research. BMJ 1995;311(6999):251-3.  
12  
13 (22) Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;(2):77-101.  
14  
15 (23) Miles MB, Huberman AM. Qualitative data analysis: an expanded sourcebook. 2nd ed.  
16 Thousand Oaks: Sage Publications; 1994.  
17  
18 (24) Shenton AK. Strategies for Ensuring Trustworthiness in Qualitative Research Projects. Educ  
19 for Infor 2004;(12):2-63.  
20  
21 (25) Mays N, Pope C. Rigour and Qualitative Research. BMJ 1995;(6997):109-12.  
22  
23 (26) Ritchie J, Spencer L, O'Connor W. Carrying out Qualitative Analysis. In: Ritchie J, Lewis J,  
24 editors. Qualitative Research Practice. 1st ed. London: SAGE; 2003. p. 219-63.  
25  
26 (27) Britten N. Commentary: Does a prescribed treatment match a patient's priorities? BMJ  
27 2003;(7419):840.  
28  
29 (28) Lincoln YS, Guba EG. But is it rigorous? Trustworthiness and authenticity in naturalistic  
30 evaluation. New Directions for Program Evaluation 2004;(30):73-84.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Doctors' understanding of individualisation of drug treatments: A qualitative interview study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002706.R1
Article Type:	Research
Date Submitted by the Author:	28-Mar-2013
Complete List of Authors:	Denford, Sarah; University of Exeter Medical School, Health Services Research Frost, Julia; University of Exeter Medical School, Health Services Research Dieppe, Paul; University of Exeter Medical School, Health Services Research Britten, Nicky; University of Exeter Medical School, Health Services Research
<b>Primary Subject Heading</b>:	Health services research
Secondary Subject Heading:	Qualitative research
Keywords:	PRIMARY CARE, QUALITATIVE RESEARCH, SOCIAL MEDICINE

SCHOLARONE™  
Manuscripts

1  
2  
3 **Doctors' understanding of individualisation of drug treatments: A qualitative interview**  
4 **study**  
5  
6

7 S Denford<sup>1</sup>, J Frost<sup>1</sup>, P Dieppe<sup>1</sup>, N Britten<sup>1</sup>  
8

9 <sup>1</sup>University of Exeter Medical School, institute of Health Services Research, Exeter, UK  
10  
11

12  
13  
14 Correspondence to:

15 Sarah Denford

16  
17 University of Exeter Medical School,  
18

19 Veysey Building,  
20

21 Salmon Pool Lane,  
22

23 Exeter, EX2 4SG  
24

25 [Sarah.denford@pms.ac.uk](mailto:Sarah.denford@pms.ac.uk)  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 Key words: Individualisation, drug treatment, self-management, chronic conditions, qualitative.  
56

57 Total word count: 5801 (abstract: 184)  
58  
59  
60

## ABSTRACT

### Objective

To explore doctors' understanding of individualisation of drug treatments, and identify the methods used to achieve individualisation.

### Design

In this exploratory study, we used in-depth qualitative interviews with doctors to gain insight into their understanding of the term 'individualised treatments' and the methods that they use to achieve it.

### Participants

Sixteen General Practitioners (GPs) in six rural and 10 urban practices, two geriatricians and two clinical academics were recruited.

### Setting

Primary and secondary care in South West of England.

### Results

Understanding of individualisation varied between doctors, and their initial descriptions of individualisation were not always consistent with subsequent examples of patients they had treated. Understandings of, and methods used to achieve individualised treatment were frequently discussed in relation to making drug treatment decisions. Few doctors spoke of using strategies to support patients to individualise their own treatments after the consultation.

### Conclusion

Despite its widespread use, variation in doctors' understanding of the term individualisation highlights the need for it to be defined. Efforts are needed to develop effective methods that would offer a structured approach to support patients to manage their treatments after consultations.

## ARTICLE SUMMARY

### Article focus

- To explore doctors' understanding of individualisation of drug treatments.
- To identify the methods used to achieve individualisation.

### Key messages

- Doctors' understanding of individualised treatments ranged from treatments that are doctor-led and evidence based to treatments that are prescribed after consideration of patients' priorities.
- Doctors' stated definitions of individualisation were not always congruent with the examples they provided from their clinical practice.
- Doctors rarely referred to patients' use of their medication after the consultation.

### Strengths and limitations

- The use of qualitative methods generated a rich insight into doctors' understanding of individualisation, methods used to achieve individualisation, and the relationships between the two.
- Strategies were used to enhance the trustworthiness of the data including multiple coders, respondent validation and triangulation of findings with the existing literature.
- However, use of opportunity sampling may have resulted in a self-selected sample.



## INTRODUCTION

Self-management is one of the foundations of chronic disease management; however, it is not straight forward. To facilitate self-management, policy makers advocate that treatments are tailored, personalised or individualised to patients' needs<sup>(1)</sup> and that patients are supported to self-manage their conditions<sup>(2)</sup>. Despite this, terms such as individualisation and personalisation are regularly used to refer to a number of different things<sup>(3)</sup>. It is often unclear as to whether individualised treatments are individualised to patients' medical needs or their personal needs<sup>(3)</sup>; which may or may not be complementary.

Successful pharmacological management of chronic disease requires appropriate drug prescribing by doctors and appropriate drug utilisation by patients. This involves (at least) three processes. First there is the interaction between the doctor and the patient within the medical consultation: the task here is to make a correct diagnosis and select appropriate treatments. Next is the doctor's prescription of appropriate drugs and dosage schedules to treat the individual patient if necessary. The third process is the patient's use of the drug in the context of their lives. This process is not linear; interactions between doctors and patients will occur both before and after the prescription has been written and further interactions between patients and doctors are likely to occur during follow-up consultations. Treatments may be individualised at any stage.

Evidence based guidelines are available to support doctors to select appropriate drugs for individual people<sup>(4,5)</sup>. However, there remains a degree of uncertainty regarding the effectiveness of certain pharmacological treatments for individual patients<sup>(6)</sup>. Results of randomised controlled trials cannot always be accurately applied to different individuals in varying socio-demographic and medical contexts<sup>(7,8)</sup>. Variation in the severity of the condition, presence of co-morbidity, genetic profile, polypharmacy, and psychosocial factors all influence the effectiveness of the treatment and the potential risk of adverse drug reactions<sup>(7)</sup>. For individuals with multiple conditions, on multiple medications, or with a new or rare condition, guidelines are often unsuitable or unavailable<sup>(9)</sup>. A large body of research promotes models of interaction or decision making such as patient centred care<sup>(10)</sup> and shared decision making<sup>(11)</sup>. These are recommended by academics and policy makers as potential solutions in which patients' views and priorities are explored and treatment decisions are negotiated<sup>(12)</sup>. Despite recommendations, these 'solutions' are not

1  
2  
3 routinely used in clinical practice<sup>(13)</sup>, and there is very little consensus about what these  
4 terms entail or how they should be implemented<sup>(13-15)</sup>.  
5

6  
7 Previous qualitative research has explored how healthcare providers make individualised  
8 treatment decisions in the face of competing priorities<sup>(16-18)</sup>. That research highlights the  
9 variation in the strategies doctors employ to make treatment decisions in such situations<sup>(16-</sup>  
10<sup>18)</sup>. Doctors vary in their use of evidence and how they resolve the tensions that are  
11 inherent in using evidence alone (such as without consideration of patients' preferences).  
12

13  
14 When faced with complex patients, doctors approach decisions with caution and  
15 uncertainty<sup>(16,19,20)</sup>.  
16

17  
18 Should a drug be prescribed, the third process is the patients' use of the drug after the  
19 consultation. In a synthesis of qualitative studies of medication taking, Pound et al found  
20 that patients' use of medication is influenced by their judgements about the relative risks  
21 and benefits of using medications, the likelihood and impact of adverse effects, and the  
22 acceptability of the treatment regime in their lives<sup>(21)</sup>. Pound et al also found evidence to  
23 suggest that patients are often motivated to minimise their use of medication - to reduce  
24 the dose of medication whilst still achieving some gain or to make the regime more  
25 acceptable or cost effective<sup>(21)</sup>. Patients actively sought answers to questions they had  
26 about their medication, for example, by stopping or lowering the dose of medication to test  
27 its effectiveness (lay testing); only taking medication when symptomatic (symptomatic use  
28 of medication); only taking medication or taking more medication to offset lifestyle factors  
29 such as drinking alcohol (strategic use of medication) and replacement of medication with  
30 non pharmacological treatments. Thus, many patients carry out their own individualisation  
31 according to their own criteria.  
32

33  
34 This project aims to explore doctors' understanding of the term 'individualised treatments' and the  
35 methods that they employ to achieve individualised treatments.  
36  
37

## 38 39 40 41 42 43 44 45 **METHODS**

### 46 47 **Design**

48  
49 In this exploratory study, we used in-depth qualitative interviews<sup>(22)</sup> with doctors to explore their  
50 understanding and clinical practice.  
51

### 52 53 54 **Sampling and data collection**

55  
56 We used opportunity sampling to recruit doctors to the study. We anticipated that individualisation  
57 would be particularly relevant to doctors who deal with patients who have a range of problems;  
58  
59

1  
2  
3 therefore we decided to sample doctors who are generalists (such as general practitioners and  
4 geriatricians). Two clinical academics (who were also hospital consultants) from within the medical  
5 school took part in pilot interviews to help test the procedure and topic guide.  
6  
7

8 We then emailed information about the study to 55 practice managers from practices on the Devon  
9 Primary Care Incentive Scheme register (a register of primary care practices who have applied for  
10 support from the Primary Care Research Network for participation in research), and asked interested  
11 doctors to make contact and arrange a time and place for the interview to take place. Sixteen  
12 doctors from 12 primary care practices responded to the email and took part in the interview. Two  
13 geriatricians were also recruited using snowball sampling. Our initial topic guide was based on a  
14 review of the literature and our own clinical experience (an experienced nurse and rheumatologist  
15 are members of the team). Open ended questions were used to explore the following topics (i)  
16 understanding of individualisation (ii) examples of individualising treatments (iii) methods used  
17 when patients' preferences are incompatible with guideline recommendations (iv) methods used to  
18 support patients to use their medication outside consultations (v) methods used to individualise  
19 treatments for patients with multiple chronic conditions and (vi) when individualisation is and is not  
20 appropriate. Participants were also asked if there was anything else they thought was relevant to  
21 individualisation. On the basis of the two pilot interviews with local clinical academics, the topic  
22 guide was modified to make it clearer that we are interested in individualised drug (as opposed to  
23 talking or physical) treatments in patients with chronic (as opposed to acute) conditions. In order to  
24 obtain detailed accounts, doctors were encouraged to provide examples of patients they had seen  
25 whenever possible.  
26  
27

28 To contextualise our study, the interviewer gave the following explanation at the beginning of the  
29 interview: *"Patients will vary in terms of the number of conditions they have, the amount of*  
30 *medications they take, and the severity of their condition(s). Patients will also have very different*  
31 *lifestyles, priorities, and beliefs about their condition(s) and treatments. We aim to explore the*  
32 *methods used by Healthcare providers to individualise treatments. We are aware that there is little*  
33 *consensus about what individualisation is, little guidance in the literature about how to do it, and*  
34 *that some doctors have developed their own approaches. We are interested in exploring the*  
35 *methods or strategies that are used by healthcare providers to tailor treatments to each individual*  
36 *patient."* The interviewer started interviews by asking participants what they understood  
37 individualization to be, and to provide an example of a time during which they had individualized  
38 treatment with a patient. To avoid influencing participants' answers, we did not explicitly define  
39 individualisation. However, the interviewer later used prompts to encourage participants to discuss  
40 additional situations that could be considered to be amenable to individualisation (as per the topic  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 guide). We anticipated that this would provide a detailed account of doctors' understanding of  
4 individualisation and the methods that they would use to achieve it within their understanding as  
5 well as the methods that they used to individualise treatments as others may see it.  
6  
7

8 All participants provided written consent prior to taking part. Ethical approval was obtained from the  
9 Peninsula College of Medicine and Dentistry ethics committee.  
10

### 11 **Data analysis**

12 Interviews were audio recorded, anonymised and transcribed verbatim. We analysed the data using  
13 a thematic approach<sup>(23)</sup>. Two researchers independently read transcripts and noted down core  
14 codes that were identified. We met regularly to discuss codes and to develop a preliminary list of  
15 themes. As analysis progressed, we drew on the existing literature to refine this list and to group  
16 related themes together<sup>(24)</sup>.  
17

18 We then developed a chart for each theme<sup>(24)</sup>, and copied any interview data that was related to  
19 each theme into the relevant chart. To enhance rigour<sup>(25)</sup>, two authors carried out this process  
20 independently. We resolved discrepancies via discussion<sup>(26)</sup>. We then used the charts to identify  
21 narratives within cases and diversity between cases<sup>(27)</sup>. Divergent cases were discussed and included  
22 in the thematic analysis<sup>(27)</sup>.  
23

24 A summary of the findings were sent to all doctors along with an invitation to offer any comments.  
25  
26

## 27 **RESULTS**

28 One author (SD) collected data between February and July 2012 from sixteen General Practitioners  
29 (GPs) (six rural and ten urban practices) and two geriatricians from clinical practices in Devon. Data  
30 from the two clinical academics who took part in the pilot interviews was also included in the  
31 analysis. Seven doctors were female. Interviews were held at a location to suit the doctors (mainly at  
32 their place of work). The mean length of the interviews was 48 minutes (range 20-60 minutes). The  
33 data are presented under three main headings. First we identified two sub-themes relating to  
34 doctors' understanding: evidence based medicine and doctor-led prescribing, and individualising  
35 treatments around patient factors. Secondly we identified two sub-themes under the heading  
36 methods used to individualise treatments: methods used to make treatment decisions during the  
37 consultation, and methods to support patients after the consultation. Thirdly we identified  
38 dissonance between the rhetoric of individualisation and doctors' clinical reports of how they had  
39 dealt with some of their patients.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

### 55 **Understanding of individualised treatment**

1  
2  
3 Doctors' understanding of individualisation ranged from evidence based medically focused, doctor-  
4 led care, through to prescribing drug treatments tailored to the patients' wishes and beliefs. There  
5 was variation in the ease with which doctors spoke about individualisation. There were two doctors  
6 who could not articulate their understanding of individualisation, but who were still able to respond  
7 to prompts about how they would deal with situations that could be considered to be amenable to  
8 individualisation. Doctors frequently discussed individualisation in relation to two of the processes  
9 involved in the prescription and use of pharmacological treatment - selecting appropriate drugs to  
10 treat the individual patient, and the interaction with the patient in the medical consultation. Doctors  
11 paid less attention to patients' use of treatments post consultation.  
12  
13

#### 14 *Evidence based medicine and doctor-led prescribing*

15  
16 At one end of the spectrum, individualisation was considered to be synonymous with evidence  
17 based practice. Focussing on the doctors' task of selecting appropriate drugs to treat the individual  
18 patient, one doctor described how the process of matching patients with guidelines resulted in all  
19 treatments being individualised:  
20  
21

22  
23 "I suppose when I did discuss it recently with my colleague the point he made was all  
24 treatments are individualised and it's, perhaps you're looking at it from a different  
25 perspective, because we look at it from the individual that comes in and then try and match  
26 a guideline to them or guidance, so everything you do is individualised anyway." (Sophie,  
27 urban GP)  
28  
29

30  
31 Importantly, when asked about their understanding of individualised treatment, no doctor referred  
32 to doctor-led prescribing specifically. However, it was implicit in their examples that in certain  
33 situations (such as if the doctor thought that the patient really could benefit from treatment), they  
34 considered a doctor-led style of prescribing to be individualised.  
35  
36

37  
38 "Well again, it's a case of looking at what is right for that particular patient at that particular  
39 time, and, I, I, because the patient was at high risk of stroke, then I did really try to push the  
40 treatment." (Jim, urban GP)  
41  
42

43  
44 "You know, because I think if, somebody might be very against a drug, but if I've  
45 seen it work really effectively in the past, I suppose I feel, I wouldn't force them to  
46 take it, if I force them to take it they won't take it anyway, but I suppose I feel if I  
47 can find a way round it that would encourage them just to give it a go, sometimes  
48 it's worth it." (Catherine, urban GP)  
49  
50

#### 51 *Individualising treatments around patient factors*

1  
2  
3 Doctors described individualised treatments as drug treatments that had been selected after  
4 consideration of patient factors (such as patient circumstances). Frequently, this meant adapting or  
5 going against guideline recommendations. Some doctors described individualised treatments as  
6 treatments that had been tailored to suit the patients' medical needs (for example, when treating  
7 patients with co-morbidities):  
8  
9

10  
11 "Well it's always checking on individual preferences, but the biggest factor is co-  
12 morbidity, that's what makes me step outside the box as it were." (Tom, urban  
13 GP)  
14  
15

16  
17 For other doctors, individualised treatments were treatments that had been adapted to  
18 suit patients' social circumstances:  
19

20  
21 "So, I've got someone who lives out the back of beyond, no transport, they might  
22 be less keen to have something that requires frequent monitoring... We have a lot  
23 of shift workers round here so that can be quite an issue, um, shifts will often  
24 change from week to week... complete nightmare controlling anything like that  
25 because they're sometimes asleep when they're supposed to be taking their pills.  
26 So they can be tricky." (Rachel, rural GP)  
27  
28  
29

30  
31 For some, individualised treatment required the patient to be involved in treatment decisions; with  
32 treatments being individualised around the patients' willingness to take a drug. These doctors  
33 considered patients' preferences to be more important than their own views and preferences. In  
34 particular, the two geriatricians in our sample were conscious that the patients' preferences are  
35 perhaps more important than achieving optimal control of their conditions:  
36  
37  
38

39  
40 "Because most of the patients that we see have reached what statistically would  
41 be regarded as their life expectancy. So there is, we can't in anyway force our  
42 opinions on them. We have to go with the fact that they have made this value  
43 judgement as to what is the right thing for them... And we just have to accept that  
44 they've made the right judgement for them. Which is not necessarily the right  
45 judgement for us. But as long as we feel that they are fully informed, or as  
46 informed as they can be, then we just accept what decisions they make on their  
47 behalf." (Mark, geriatrician)  
48  
49  
50

51  
52 "Maybe that's easier in geriatrics where we know lots of what we do comes at a  
53 price, we know 10% of hospital admissions that we do are from drug side effects.  
54 So maybe we feel a bit more relaxed about it." (William, geriatrician)  
55  
56  
57  
58  
59  
60

1  
2  
3 For others, individualising treatment in accordance with the patients' willingness to take a  
4 drug simply meant accepting that the patient had declined treatment:  
5

6  
7 "And I'm quite happy to agree to differ, if they want to decline treatment, I'd write  
8 down declined treatment. I think it's important to come back to, not just see it as  
9 something that they've done wrong, but it's fine for them to do that, and I don't  
10 have a problem with them not taking that treatment." (Marcus, urban GP)  
11  
12

### 13 **Methods used to individualise treatments**

14  
15 Doctors described the methods they used to achieve individualisation. Again, doctors focused on the  
16 methods used to select appropriate drugs to treat individuals and interactions with the patients  
17 during the consultation. Few doctors spoke of methods to support the patient to use treatments  
18 after the consultation when drug taking actually occurs. *Methods used to make treatment decisions*  
19 *during the consultation*  
20  
21

22  
23 Doctors described using a range of resources to select appropriate drugs to treat individual patients.  
24 These included evidence, clinical experience, colleague support, and the patients' views or  
25 circumstance. Use of resources was dependent on doctors' understanding of individualisation, but  
26 influenced by the patient and the situation. All doctors described using evidence to make treatment  
27 decisions. However, views about the role of the evidence varied between doctors:  
28  
29  
30  
31

32  
33 "EBM is only one of many strategies, and, it's like you've got a tool box you know? And the  
34 tool that you use every time is you yourself. And you need, and you can learn to do that  
35 better. I'm very interested in that. And then occasionally you'll pull EBM out as well. But not,  
36 you know, not very often. Honestly, I would think I probably, as a first tool that you pull out,  
37 it would probably be once or twice a day." (Andrew, urban GP)  
38  
39  
40

41  
42 It was widely acknowledged that "text book" scenarios were rare. One general practitioner reported  
43 that most of his patients had complex social needs, and both the geriatricians in our sample  
44 reported that nearly all of their patients had multiple conditions. These complex patients could not  
45 be treated only using evidence based guidelines<sup>9</sup>). Treatment decisions for patients with complex  
46 needs were made based on their own or their colleagues' clinical experience:  
47  
48

49  
50 "Often we send messages to each other. I share a list with another GP colleague,  
51 and we share difficult patients, and discuss how are we going to get Mr so and so  
52 to do X, Y and Z?" (Sophie, urban GP)  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 To treat patients with complex needs, doctors often made treatment decisions for the patient, using  
4 strategies like polypharmacy to deal with side-effects of treatments, and accepting that not all  
5 conditions can be optimally managed:  
6  
7

8 “Interviewer (I): Ok, so when you’ve got a patient who comes in and has a range of medical  
9 conditions, and you know if you treat all of them it’s going to lead to interactions?  
10

11 Respondent (R): The regimens for each of these conditions, A, B and C are reasonably well  
12 sorted because they’re common conditions, common drugs, usually sorted. So he has  
13 arthritis, diabetes and epilepsy. That’s a nice juicy mix, and fairly common. By and large you  
14 will get away with this polypharmacy.” (Mathew, urban GP)  
15  
16  
17

18 To involve the patient in the treatment decisions, doctors reported using techniques such as  
19 providing the patient with the information needed to make an informed choice, suggesting  
20 treatment and outcome options, and giving the patient time to think about their priorities:  
21  
22  
23

24 “And then we can provide them with alternatives like ‘well this will cure that but  
25 this could affect your kidneys. This might not have as big an effect on that but it  
26 would preserve the kidneys and could leave you a little bit short of breath. Of  
27 those two which would you rather have? The risk of feeling completely healthy,  
28 but potentially shorter life, or having some symptoms but a longer life?’ And  
29 working with those decisions.” (Mark, geriatrician)  
30  
31  
32  
33

34 Whilst one doctor aimed to prescribe treatments in accordance with patients’ interests, he  
35 accepted that this could not be an everyday occurrence:  
36  
37

38 “I’ll be honest; I don’t do it all the time, so I don’t want to pretend I’m perfect at  
39 this. I think the clearest one that I’ve got is a bloke in his late 50s with Parkinson’s  
40 who’d retired, but the thing that kept him going was that he could go to the  
41 swimming pool every morning... So we opted for a patch for him... You slap it on  
42 once a day and it gives you 24 hour coverage so he could put it on the night  
43 before and he’d be switched on in the morning, he wasn’t waiting for a tablet to  
44 kick in and make him work. And it worked beautifully for him... but after a few  
45 months he got skin reactions and we had to stop it and find something else, but  
46 that really felt like we had really picked a drug around him and his interests and  
47 what was keeping him going.” (William, geriatrician)  
48  
49  
50  
51  
52  
53  
54

55 Interviewees also reported situations in which a more directive approach was considered to  
56 be necessary. This included situations in which patients’ goals were deemed unrealistic, or  
57  
58  
59  
60



1  
2  
3 when the doctor thought that the patient really should be using some form of treatment.  
4 Doctors then reported using techniques in order to convince or persuade the patient to  
5 follow recommendations. In some cases, attempts were made to encourage the patient to  
6 see the medical imperative for treatment:  
7  
8

9  
10 “They don't want to take any tablets; you say ‘well you probably will die in 5 years time at  
11 the most without these things. If you take these things it might prolong your life, by this that  
12 or the other.’” (Joe, urban GP)  
13  
14

15 For some doctors, the assumption appeared to be that the patient was in some way misinformed.  
16 Therefore, attempts were made to educate the patient:  
17

18  
19 “Most of the time you can explain to people why they ought to be taking  
20 something and hopefully they might come round to thinking that that’s the best  
21 thing to do. Sometimes people might have different ideas and won’t take anything  
22 or certainly won’t take what you suggest but I think most of the time you can  
23 explain to people why or what the evidence is or what the consensus is. And most  
24 of the time if people understand it they’ll take it.” (Lynn, rural GP)  
25  
26  
27  
28

29 If initial treatment decisions were not acceptable to the patient, attempts were made to  
30 change or simplify the regime or to prescribe alternative treatments:  
31

32  
33 “You just say ‘well let’s try something else.’ The nice thing is, there’s always, or very  
34 often there’s always alternatives that are either as good or, uh, you know, in the  
35 same league.” (Sophie, urban GP)  
36  
37

### 38 *Methods used to support patients after the consultation*

39  
40 In most interviews, individualisation was described in the context of making treatment  
41 decisions during the consultation. Few doctors spoke of methods to support patients to test  
42 and refine their treatment in the context of their own life. To support patients after the  
43 consultation, doctors reported using techniques such as reminders and instructions. This  
44 ranged from standardised monitored dosage system or text messaging services, to writings  
45 and drawings on prescription labels. Crucially, the aim of such strategies was to help the  
46 patient use their medications as prescribed:  
47  
48  
49  
50

51  
52 “I: Do you use any strategies to support the patients outside the consultation?  
53

54 R: Um, not enough. It’s something I often think about that I should be doing more.  
55 So I do drawings and write things on bits of scrap paper, about if there is a  
56  
57  
58  
59  
60

1  
2  
3 complicated medication, or a list of things to do, or if people are older, forgetful”

4 (Marcus, urban GP)  
5

6 A minority of doctors described using strategies to help patients modify treatment regimes  
7 to suit their lives. One geriatrician described how he used techniques such as separating  
8 drugs into those that have to be taken (to treat the condition) and those that do not have  
9 to be taken (to treat the symptoms):  
10

11  
12  
13 “I tend to rearrange them so into treatments and symptoms... And if you group  
14 them like that, then if they get half way through the tablets, providing they’ve  
15 taken their treatment tablets, the symptom control, if they don’t take it they’re  
16 going to feel lousy, but the balance between taking a tablet or not taking a tablet,  
17 it’s not going to make any difference to their longer term health.” (Mark,  
18 geriatrician)  
19  
20  
21  
22

23 Another geriatrician described a process of trial and error, in which drugs were used for a  
24 period of time and then modified by the doctor if necessary:  
25

26  
27 “I think as well, because we tell patients for a lot of these drugs let’s try this and  
28 see if it works, if it’s not working we’ll stop it. It allows patients to come back and  
29 say it’s not working rather than come back and feel that they’re on it.” (William,  
30 geriatrician)  
31  
32  
33

34 Only one general practitioner actively encouraged patients to modify their treatments to  
35 achieve individualised doses. This doctor described reluctance on behalf of some patients  
36 to do so:  
37

38  
39 “So actually, for an awful lot of drugs, I do this all the time. I say balance up your,  
40 you know yourself when you’re getting the side effects. Titrate the medication until  
41 you’re just below the level at which you get the side effects and fiddle around with  
42 it... And then sometimes the patient’s say, ‘ohh, but it says once a day and bla bla  
43 bla.’” (Joe, urban GP)  
44  
45  
46  
47

48 The hospital consultants in our sample reported used diaries and graph paper to either  
49 assess the effectiveness of treatments and treatment doses, or to encourage patients to  
50 respond to worsening symptoms:  
51

52  
53 “So, it’s just a piece of paper really with days of the week and what their  
54 Parkinson’s is like. But Parkinson’s you swing from being on, when you can move  
55 around, to being off, when you’re frozen and stuck. So if we’re trying to give a drug  
56  
57  
58  
59  
60

1  
2  
3 to reduce the amount of time people are off , we'll often give them a diary so you  
4 can graphically see whether it's worked or not." (William, geriatrician)

5  
6  
7 "Well they all get the graph paper. And it's "If it goes above this line, phone us and  
8 we'll see you in clinic straight away. Or, if it goes above this line increase your  
9 tablets. Or do this that or the other." And it's what we tell them to do when it  
10 reaches that point that varies by patients." (Mark, geriatrician)

11  
12  
13 The question of whether or not patients needed to be encouraged to monitor symptoms  
14 was contested. Some doctors were of the opinion that patients should not be encouraged  
15 to monitor their symptoms or side-effects of their treatments:  
16

17  
18  
19 "I quite often don't tell people about the side effects of tablets, which is against  
20 our, against all the modern day teachings that you must tell people of the risks.  
21 Well I often don't. Because there's a lot of evidence for this, there's a type of  
22 patient that if you tell them there is a possibility that they'll get headaches, they'll  
23 get headaches." (John, clinical academic)

24  
25  
26 Others felt that patients should be told what potential side effects they should look out for:

27  
28  
29 "Explain to them the possibility that one thing might affect another and what to  
30 look out for. So if there are going to be interactions, what they, what they need to  
31 be um, coming back with um, if certain symptoms present. You know if you get this,  
32 come back, because that's a side effect we need to know about." (Becky, urban GP)

33  
34  
35 However, even with clear instructions, mistakes could happen:

36  
37  
38 "We've had that with a patient who used, you know, he had the line [indicating safe  
39 blood pressure readings], he went way below the line, kept on going without  
40 bothering to phone anyone, and six weeks later he was in hospital with renal  
41 failure. And we gave him pretty clear instructions. He decided to ignore them... It  
42 worked; he just didn't follow the instructions. But you can't do anything about that.  
43 Patients are entitled to do what they want." (Mark, geriatrician)

44  
45  
46 There was wide acceptance that, in the end, the final treatment decision was down to the  
47 patient. In certain situations, no treatment could be the best option:

48  
49  
50 "You know, you say, 'this is what's going on, you tried them we've looked at  
51 physiotherapy, we've looked at other alternatives, are your symptoms  
52 manageable? Are the treatments worse than the condition, and if they are, then  
53 maybe you need to learn to live with the condition.'" (Rachel, rural GP)

## Dissonance between rhetoric and experience

Whilst all but two doctors were able to describe their understanding of individualisation when asked, these answers did not always match the examples they provided when talking about patients they had treated. For example, one doctor described individualisation as being:

“All sorts of things. Everything from the persons’ views or thoughts about - if you’re talking about medicines - about drugs and what they want. But similarly that fits with their views of whether they like medicine, don’t like medicine, what they want in terms of getting better.” (Catherine, urban GP).

However, when this participant was asked how she would respond to a patient who did not want to use the treatment that she had prescribed, she responded:

“There are even times when I’ll say ‘well actually I think this would be worth trying’ even if they’re not very keen. And I’ll say to them ‘how about you give it a go for two weeks and see how you feel.’ You know, because I think somebody might be very against a drug, but if I’ve seen it work really effectively in the past, I suppose I feel, I wouldn’t force them to take it, if I force them to take it they won’t take it anyway, but I suppose I feel if I can find a way round it that would encourage them just to give it a go, sometimes it’s worth it” (Catherine, urban GP).

This dissonance between rhetoric and experience was evident throughout the interviews. Whilst doctors appeared to think that individualising treatments around patients’ preferences and world views into treatment decisions was of value, in practice this was not always considered to be the best strategy.

## DISCUSSION

### Main findings and comparisons with other studies

This paper presents a range of doctors’ understandings of the meaning of individualised drug treatment. Individualised treatment was discussed in relation to both treatment that was tailored to patients’ priorities, and treatment that was doctor-led and followed evidence based guidelines. Furthermore, there was a lack of congruence between doctors’ stated definition of individualisation and the examples they provided from their practice. Doctors frequently spoke of methods to support interactions during consultations, the first of the processes referred to in the introduction of this paper. However, despite the findings of Pound et al<sup>(21)</sup>, doctors in our study infrequently mentioned patients’ use of their medications outside the consultations.

1  
2  
3 The main strength of this study is the use of qualitative methods to generate a rich insight into  
4 doctors' understanding of individualisation, methods used to achieve individualisation, and the  
5 relationships between the two. We used strategies to enhance the trustworthiness of our study,  
6 including multiple coders and respondent validation. We triangulated our findings with the existing  
7 literature, and asked participants to comment on our findings<sup>(28)</sup>. Participants who took part in pilot  
8 interviews stated that they could recognise our findings, and agreed that they were plausible.

9  
10  
11 Our study was based on a sample of hospital consultants and general practitioners from the South  
12 West of England. That doctors were only recruited from this area could limit the transferability of  
13 the results, although participants had both trained and practised beyond this region. We  
14 acknowledge that our use of opportunity sampling may have resulted in a self-selected sample.  
15 However, as we are interested in best practice, we were not overly concerned with recruiting only  
16 those with an interest in the study.

17  
18  
19 Previous qualitative research has explored methods to support doctors during consultations<sup>(16-18)</sup>. In  
20 those studies, the focus was on strategies used by doctors to make individualised prescribing  
21 decisions within the medical consultation - where guidelines may not be appropriate. Similar to the  
22 doctors in our study, those studied by Fried et al. had variable views about how treatment decisions  
23 for patients with complex conditions should be made. Use of evidence and strategies to balance the  
24 harms versus the benefits of guideline directed care varied between physicians.

25  
26  
27 Doctors in both of these studies had differences of opinion regarding the role of the patient in  
28 treatment decisions. For some, treatment decisions should be doctor-led, with the doctor  
29 persuading the patient to use the treatment that they thought would be most appropriate. For  
30 others, patient involvement was an essential component of treatment decisions. A number of  
31 doctors reported that integrating patients' preferences into medical decisions was problematic if the  
32 treatment was essential. This was still a major concern for many doctors, despite research  
33 suggesting that patients' and doctors' priorities may be very different<sup>(29)</sup>. This paternalism versus  
34 patient choice is an ongoing debate, and one that is widely discussed in the literature<sup>(15;30;31)</sup>. In the  
35 current paper, the dissonance between the rhetoric of individualisation and doctors' clinical  
36 behaviour appeared to stem from this issue, with the data revealing tensions between doctors  
37 desire to treat the patients' social needs, whilst simultaneously treating their medical needs.

38  
39  
40 Pound et al found evidence to suggest that patients actively modify their medications in order to suit  
41 their lives<sup>(21)</sup>. However, there is a paucity of literature surrounding methods used to support  
42 patients during this third process. The few doctors in our study who spoke of methods to support  
43 patients outside the consultation described methods such as sorting drugs by their role (to treat or  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 to cure), trial and error, and monitoring. These strategies are largely informal: for example,  
4 drawings, or writing about the use of the medication on bits of paper. The limitations of such  
5 informal methods were acknowledged.  
6  
7

8  
9 The lack of consideration of what goes on outside the consultation is particularly interesting and  
10 worrying. Pound et al., (2005) has shown that many patients will monitor their symptoms and side  
11 effects and make treatment adaptations as necessary – with or without the support of the doctor.  
12 Self-management of chronic disease requires patients to take multiple treatments and monitor their  
13 health over many years. Therefore, strategies to support patients to modify treatments, and  
14 providing safe parameters for them to do so, may actually limit patient driven amendments to  
15 treatments without professional support. However, our study highlights the variation in opinions  
16 about whether or not patients should be encouraged to adapt treatments after consultations. One  
17 doctor felt that patients did not want to adapt their treatments. Another doctor thought that  
18 encouraging patients to be aware of side-effects could actually contribute to side effects. Others  
19 were concerned that encouraging patients to monitor symptoms could lead to unnecessary stress.  
20 Only a small number of doctors thought that patients should be encouraged to individualise  
21 treatments after the consultation. In particular, the two geriatricians seemed to have a better  
22 understanding of, and a larger set of methods to support patients to individualise treatments after  
23 consultations than the general practitioners, thus suggesting that the findings might be related to  
24 medical subspecialty. Further research is needed to explore differences in individualisation between  
25 different clinical specialities, as this may highlight situations clinical areas in which individualisation is  
26 commonly achieved, and situations in which individualisation is not so appropriate.  
27  
28

29  
30 The findings reported here have important implications for research and practice. The focus of this  
31 study was on the strategies and methods that doctors used to reach decisions within the  
32 consultation. Few doctors discussed methods to support patients to use drug treatments outside the  
33 consultation. Methods that were suggested were informal and unstructured, and doctors  
34 acknowledged that such methods may neither be supportive enough or measurable. Furthermore,  
35 doctors perceived a number of barriers to individualising treatments after the consultation; such as  
36 whether or not strategies could contribute to side-effects and cause unnecessary stress. Before  
37 policy recommendations concerning both individualisation and self-management can be achieved  
38 commissioners need to be clear about what they are advocating, thus, the concept of  
39 individualisation needs to be refined. Methods used to achieve individualisation may then be  
40 developed and piloted in different situations. Such methods should be appropriately structured to  
41 be supportive and their effects measurable. Given that some patients are already individualising  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 treatments on their own, supporting patients to do so safely could improve patients' self-  
4 management practices.  
5  
6  
7

### 8 **Acknowledgements**

9  
10 We would like to thank the participants who took part in the research.  
11

### 12 **Competing interests**

13 All authors have completed the ICMJE uniform disclosure at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf)  
14 (available on request from the corresponding author) and declare: SD's time is funded by NIHR; no  
15 financial relationships with any organizations that might have an interest in the submitted work in  
16 the previous three years; no other relationships or activities that could appear to have influenced  
17 this work.  
18  
19  
20  
21  
22

### 23 **Funding**

24 This article presents independent research funded by the National Institute for Health Research  
25 (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for the South  
26 West Peninsula. The views expressed in this publication are those of the author(s) and not  
27 necessarily those of the NHS, the NIHR or the Department of Health in England  
28  
29  
30  
31  
32

### 33 **Copyright**

34 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of  
35 all authors, a worldwide license to the Publishers and its licensees in perpetuity, in all forms, formats  
36 and media (whether known now or created in the future), to i) publish, reproduce, distribute, display  
37 and store the Contribution, ii) translate the Contribution into other languages, create adaptations,  
38 reprints, include within collections and create summaries, extracts and/or, abstracts of the  
39 Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all  
40 subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to  
41 third party material where-ever it may be located; and, vi) license any third party to do any or all of  
42 the above.  
43  
44  
45  
46  
47  
48

### 49 **Contributions and guarantor**

50 All four authors had a substantial contribution to the conception and design of the research. The  
51 analysis and interpretation of the data was undertaken by Sarah Denford, with considerable input  
52 from Julia Frost, Nicky Britten and Paul Dieppe. The article was drafted by Sarah Denford, and  
53 revised by the remaining three authors. All four authors approved the final version of the article  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 before publication. There were no other contributors that are not included as an author. Sarah  
4 Denford is the guarantor.  
5

6  
7 **Data sharing**

8  
9 Full dataset is available from the corresponding author at Sarah.denford@pms.ac.uk. Consent was  
10 not obtained but the presented data are anonymised and risk of identification is low.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## REFERENCE LIST

- (1) Department of Health. Equity and excellence: Liberating the NHS. Stationary Office, 2010.
- (2) Department of Health. Supporting people with long term conditions. Stationary Office, 2005.
- (3) Cribb A, Owens J. Whatever suits you: unpicking personalization for the NHS. *J Eval Clin Pract* 2010;16(2):310-4.
- (4) Haynes RB, Sackett DL, Gray JM, et al. Transferring evidence from research into practice: 1. The role of clinical care research evidence in clinical decisions. *ACP J Club* 1996 Nov;125(3):A14-A16.
- (5) Hayward RS, Wilson MC, Tunis SR, et al. Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence-Based Medicine Working Group. *JAMA* 1995 Aug 16;274(7):570-4.
- (6) Evans I, Thornton H, Chalmers I, et al. Testing treatments better research for better healthcare. London: Pinter & Martin, 2010.
- (7) Kravitz RL, Duan N, Braslow J. Evidence-Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages. *Mil Quart* 2004;82(4):661-87.
- (8) Mant D. Can randomised trials inform clinical decisions about individual patients? *Lancet* 1999;353(9154):743-6.
- (9) Boyd CM, Darer J, Boulton C, et al. Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid Diseases. *JAMA* 2010;294(6):716-24.
- (10) Lewin S, Skea Z, Entwistle VA, et al. Interventions for providers to promote a patient-centred approach in clinical consultations (Cochrane review). *Cochrane Libr* 2012; 2001;(4):CD003267.
- (11) Marshall M, Bibby J. Supporting patients to make the best decisions. *BMJ* 2011;342:d2117.
- (12) Agedahl KM, Gulbrandsen P, Forde R, et al. Courteous but not curious: how doctors' politeness masks their existential neglect. A qualitative study of video-recorded patient consultations. *J Med Ethics* 2011;(24)107-113.
- (13) Richards N, Coulter A. Is the NHS Becoming more Patient-centred? Trends from the National Surveys of NHS Patients in England 2002-07. London: Picker Institute; 2007.
- (14) Cribb A, Entwistle VA. Shared decision making: trade-offs between narrower and broader conceptions. *Health Expect* 2011;14(2):210-9.
- (15) Sandman L, Munthe C. Shared decision making, paternalism and patient choice. *Health Care Anal* 2010;18(1):60-84.
- (16) Anderson N, Fuller R, Dudley N. 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. *QJM* 2007;100(5):263-9.

- 1  
2  
3 (17) Fried T, Tinetti ME, Iannone L. Primary Care Clinicians' Experiences With Treatment Decision  
4 Making for Older Persons With Multiple Conditions. *Arch Intern Med* 2011;171(1):75-80.  
5  
6 (18) Luijckx HD, Loeffen MJ, Lagro-Janssen AL, et al. GPs' considerations in multimorbidity  
7 management: a qualitative study. *Br J Gen Pract* 2012;62:e503-e510.  
8  
9 (19) Schattner A, Fletcher RH. Research evidence and the individual patient. *QJM* 2003;96(1):1-5.  
10  
11 (20) Griffiths F, Green E, Tsouroufli M. The nature of medical evidence and its inherent  
12 uncertainty for the clinical consultation: qualitative study. *BMJ* 2005;330(7490):511.  
13  
14 (21) Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of  
15 medicine taking. *Soc Sci Med* 2005;61(1):133-55.  
16  
17 (22) Britten N. Qualitative interviews in medical research. *BMJ* 1995;311(6999):251-3.  
18  
19 (23) Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;(2):77-101.  
20  
21 (24) Miles MB, Huberman AM. *Qualitative data analysis: an expanded sourcebook*. 2nd ed.  
22 Thousand Oaks: Sage Publications; 1994  
23  
24 (25) Shenton AK. Strategies for Ensuring Trustworthiness in Qualitative Research Projects. *Educ*  
25 *for Infor* 2004;(12):2-63.  
26  
27 (26) Mays N, Pope C. Rigour and Qualitative Research. *BMJ* 1995;(6997):109-12.  
28  
29 (27) Ritchie J, Spencer L, O'Connor W. Carrying out Qualitative Analysis. In: Ritchie J, Lewis J,  
30 editors. *Qualitative Research Practice*. 1st ed. London: SAGE; 2003. p. 219-63.  
31  
32 (28) Lincoln YS, Guba EG. But is it rigorous? Trustworthiness and authenticity in naturalistic  
33 evaluation. *New Directions for Program Evaluation* 2004;(30):73-84.  
34  
35 (29) Britten N. Commentary: Does a prescribed treatment match a patient's priorities? *BMJ*  
36 2003;(7419):840.  
37  
38 (30) Coulter A. Paternalism or partnership? *BMJ* 1999; (7212):719-20.  
39  
40 (31) Upton J, Fletcher M, Madoc-Sutton H, et al. Shared decision making or paternalism in  
41 nursing consultations? A qualitative study of primary care asthma nurses' views on sharing  
42 decisions with patients regarding inhaler device selection. *Health Expectations* 2011;  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Doctors' understanding of individualisation of drug treatments: A qualitative interview**  
4 **study**  
5  
6

7 S Denford<sup>1</sup>, J Frost<sup>1</sup>, P Dieppe<sup>1</sup>, N Britten<sup>1</sup>  
8

9 <sup>1</sup>University of Exeter Medical School, institute of Health Services Research, Exeter, UK  
10  
11

12  
13  
14 Correspondence to:

15 Sarah Denford

16  
17 University of Exeter Medical School,  
18

19 Veysey Building,  
20

21 Salmon Pool Lane,  
22

23 Exeter, EX2 4SG  
24

25 [Sarah.denford@pms.ac.uk](mailto:Sarah.denford@pms.ac.uk)  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 Key words: Individualisation, drug treatment, self-management, chronic conditions, qualitative.  
56

57 Total word count: 5801 (abstract: 184)  
58  
59  
60

## ABSTRACT

### Objective

To explore doctors' understanding of individualisation of drug treatments, and identify the methods used to achieve individualisation.

### Design

In this exploratory study, we used in-depth qualitative interviews with doctors to gain insight into their understanding of the term 'individualised treatments' and the methods that they use to achieve ~~it, individualised treatments.~~

### Participants

Sixteen General Practitioners (GPs) in six rural and 10 urban practices, ~~two geriatricians and two clinical academics and four hospital consultants~~ were recruited.

### Setting

~~Doctors from p~~Primary and secondary care in South West of England.

### Results

Understanding of individualisation varied between doctors, and ~~their~~ initial descriptions of individualisation were not always consistent with ~~subsequent examples~~ ~~examples of patients they had treated~~ ~~given~~. Understandings of, and methods used to achieve individualised treatment were frequently discussed in relation to making drug treatment decisions. Few doctors spoke of using ~~tools~~ ~~strategies~~ to support patients to individualise their own treatments after the consultation.

### Conclusion

Despite its widespread use, variation in doctors' understanding of the term individualisation highlights the need for it to be defined. Efforts are needed to develop effective ~~tools~~ ~~methods that would offer a structured approach~~ to support patients to manage their treatments after consultations. ~~Such a tool would offer a structured approach to support patients to self-manage their condition.~~

## ARTICLE SUMMARY

### Article focus

- To explore doctors' understanding of individualisation of drug treatments.
- To identify the methods used to achieve individualisation.

### Key messages

- ~~Doctors' understanding of individualised treatments ranged from~~ ~~There is a lack of consensus about whether individualised~~ treatments that are doctor-led ~~and~~ evidence based ~~treatments, or to~~ treatments that are prescribed after consideration of patients' priorities.
- Doctors' stated definitions of individualisation were not always congruent with the examples they provided from their clinical practice.
- Doctors rarely referred to patients' use of their medication after the consultation.

### Strengths and limitations

- The use of qualitative methods generated a rich insight into doctors' understanding of individualisation, methods used to achieve individualisation, and the relationships between the two.
- Strategies were used to enhance the trustworthiness of the data including multiple coders, respondent validation and triangulation of findings with the existing literature.
- However, use of opportunity sampling may have resulted in a self-selected sample.

## INTRODUCTION

Self-management is one of the foundations of chronic disease management; however, it is self-management is not straight forward. To facilitate self-management, pPolicy makers initiatives advocate that treatments are tailored, personalised or individualised to patients' needs<sup>(1)</sup> and that patients are supported to self-manage their conditions<sup>(2)</sup>. Despite this, However, terms such as individualisation and personalisation are regularly used to refer to a number of different things<sup>(3)</sup>. It is often unclear as to whether individualised treatments are individualised to patients' medical needs or their personal needs<sup>(3)</sup>; which may or may not be complementary.

Successful pharmacological management of chronic disease requires appropriate drug prescribing by doctors and appropriate drug utilisation by patients. This involves (at least) three processes. First there is the interaction between the doctor and the patient within the medical consultation: the task here is to make a correct diagnosis and select appropriate treatments. Next is the doctor's prescription of appropriate drugs and dosage schedules to treat the individual patient if necessary. The third process is the patient's use of the drug in the context of their lives. This process is not linear; interactions between doctors and patients will occur both before and after the prescription has been written and further interactions between patients and doctors are likely to occur during follow-up consultations. Treatments may be individualised at any stage.

Evidence based guidelines are available to support doctors to select appropriate drugs for individual people<sup>(4,5)</sup>. However, there remains a degree of uncertainty regarding the effectiveness of certain pharmacological treatments for individual patients<sup>(6)</sup>. Results of randomised controlled trials cannot always be accurately applied to different individuals in varying socio-demographic and medical contexts - patients<sup>(7,8)</sup>. Variation in the severity of the condition, presence of co-morbidity, genetic profile, polypharmacy, and psychosocial factors all influence the effectiveness of the treatment and the potential risk of adverse drug reactions<sup>(7)</sup>. For individuals with multiple conditions, on multiple medications, or with a new or rare condition, guidelines are often unsuitable or unavailable<sup>(9)</sup>. A large body of research promotes models of interaction or decision making such as patient centred care<sup>(10)</sup> and shared decision making<sup>(11)</sup>. These are recommended by academics and policy makers as potential solutions in which patients' views and priorities are explored and treatment decisions are negotiated<sup>(12)</sup>. Despite recommendations, these 'solutions' are not

1  
2  
3 routinely used in clinical practice<sup>(13)</sup>, and there is very little consensus about what these  
4 terms entail or how they should be implemented<sup>(13-15)</sup>.  
5  
6

7 Previous qualitative research has explored how healthcare providers make individualised  
8 treatment decisions in the face of competing priorities<sup>(16-18)</sup>. That research highlights the  
9 variation in the strategies doctors employ to make treatment decisions in such situations<sup>(16-  
10 18)</sup>. Doctors vary in their use of evidence and how they resolve the tensions that are  
11 inherent in using evidence alone (~~i.e., such as~~ without consideration of patients'  
12 preferences). When faced with complex patients, doctors approach decisions with caution  
13 and uncertainty<sup>(16;19;20)</sup>.  
14  
15

16 Should a drug be prescribed, the third process is the patients' use of the drug after the  
17 consultation. In a synthesis of qualitative studies of medication taking, Pound et al found  
18 that patients' use of medication is influenced by their judgements about the relative risks  
19 and benefits of using medications, the likelihood and impact of adverse effects, and the  
20 acceptability of the treatment regime in their lives<sup>(21)</sup>. Pound et al [also](#) found evidence to  
21 suggest that patients are often motivated to minimise their use of medication - to reduce  
22 the dose of medication whilst still achieving some gain or to make the regime more  
23 acceptable or cost effective<sup>(21)</sup>. Patients actively sought answers to questions they had  
24 about their medication, for example, ~~by modifying their treatment regimes~~ by stopping or  
25 lowering the dose of medication to test its effectiveness (lay testing); only taking  
26 medication when symptomatic (symptomatic use of medication); only taking medication or  
27 taking more medication to offset lifestyle factors such as drinking alcohol (strategic use of  
28 medication) and replacement of medication with non pharmacological treatments. Thus,  
29 many patients carry out their own individualisation according to their own criteria.  
30  
31

32 This project aims to explore doctors' understanding of the term 'individualised treatments' and the  
33 methods that they employ to achieve individualised treatments.  
34  
35

## 36 METHODS

### 37 Design

38 In this exploratory study, we used in-depth qualitative interviews<sup>(22)</sup> with doctors to explore their  
39 understanding and clinical practice.  
40  
41

### 42 Sampling and data collection

43 We used opportunity sampling to recruit doctors to the study. [We anticipated that individualisation  
44 would be particularly relevant to doctors who deal with patients who have a range of problems;](#)  
45  
46  
47

1  
2  
3 therefore we decided to sample doctors who are generalists (such as general practitioners and  
4 geriatricians). Two clinical academics (who were also hospital consultants) from within the medical  
5 school took part in pilot interviews to help test the procedure and topic guide.  
6  
7

8 We then emailed information about the study to 55 practice managers from practices on the Devon  
9 Primary Care Incentive Scheme register (a register of primary care practices who have applied for  
10 support from the Primary Care Research Network for participation in research), and asked interested  
11 doctors to make contact and arrange a time and place for the interview to take place. Sixteen  
12 doctors from 12 primary care practices responded to the email and took part in the interview. Two  
13 geriatricians were also recruited using snowball sampling. Our initial topic guide was based on a  
14 review of the literature and our own clinical experience (an experienced nurse and rheumatologist  
15 are members of the team). We used open ended questions to explore doctors' understanding of  
16 individualisation and the methods or strategies that they employ to deal with situations that require  
17 individualised treatment. In order to obtain detailed accounts, doctors were encouraged to provide  
18 examples whenever possible. Open ended questions were used to explore the following topics (i)  
19 understanding of individualisation (ii) examples of individualising treatments (iii) methods used  
20 when patients' preferences are incompatible with guideline recommendations (iv) methods used to  
21 support patients to use their medication outside consultations (v) methods used to individualise  
22 treatments for patients with multiple chronic conditions and (vi) when individualisation is and is not  
23 appropriate. Participants were also asked if there was anything else they thought was relevant to  
24 individualisation. On the basis of the two pilot interviews with local clinical academics, the topic  
25 guide was modified to make it clearer that we are interested in individualised drug (as opposed to  
26 talking or physical) treatments in patients with chronic (as opposed to acute) conditions. In order to  
27 obtain detailed accounts, doctors were encouraged to provide examples of patients they had seen  
28 whenever possible.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 To contextualise our study, the interviewer gave the following explanation at the beginning of the  
44 interview: "Patients will vary in terms of the number of conditions they have, the amount of  
45 medications they take, and the severity of their condition(s). Patients will also have very different  
46 lifestyles, priorities, and beliefs about their condition(s) and treatments. We aim to explore the  
47 methods used by Healthcare providers to individualise treatments. We are aware that there is little  
48 consensus about what individualisation is, little guidance in the literature about how to do it, and  
49 that some doctors have developed their own approaches. We are interested in exploring the  
50 methods or strategies that are used by healthcare providers to tailor treatments to each individual  
51 patient." The interviewer started interviews by asking participants what they understood  
52 individualization to be, and to provide an example of a time during which they had individualized  
53  
54  
55  
56  
57  
58  
59  
60



treatment with a patient. To avoid influencing participants' answers, we did not explicitly define individualisation. However, the interviewer later used prompts to encourage participants to discuss additional situations that could be considered to be amenable to individualisation (as per the topic guide). We anticipated that this would provide a detailed account of doctors' understanding of individualisation and the methods that they would use to achieve it within their understanding as well as the methods that they used to individualise treatments as others may see it.

All participants provided written consent prior to taking part. Ethical approval was obtained from the Peninsula College of Medicine and Dentistry ethics committee.

### Data analysis

Interviews were audio recorded, anonymised and transcribed verbatim. We analysed the data using a thematic approach<sup>(23)</sup>. Two researchers independently read transcripts and noted down core codesthemes that were identified. We met regularly to discuss codes themes and to develop a preliminary list of themescodes. As analysis coding progressed, we drew on the existing literature to refine this list and to group related themes together<sup>(24)</sup>.

We then developed a chart for each theme<sup>(24)</sup>, and copied any interview data that was related to each theme into the relevant chart. To enhance rigour<sup>(25)</sup>, two authors carried out this process independently. We resolved discrepancies via discussion<sup>(26)</sup>. We then used the charts to identify narratives within cases and diversity between cases<sup>(27)</sup>. Divergent cases were discussed and included in the thematic analysis<sup>(27)</sup>.

A summary of the findings were sent to all doctors along with an invitation to offer any comments.

## RESULTS

One author (SD) collected data between February and July 2012 from sixteen General Practitioners (GPs) (six rural and ten urban practices) and two geriatricians four hospital consultants from clinical practices in Devon. Data from the two clinical academics who took part in the pilot interviews was also included in the analysis. Seven doctors were female. Interviews were held at a location to suit the doctors (mainly at their place of work). The mean length of the interviews was 48 minutes (range 20-60 minutes). Interviews lasted between twenty and sixty minutes.

The data are presented under threewe main headings. First we identified two sub-themes relating to doctors' understanding: evidence based medicine and doctor-led prescribing, and individualising treatments around patient factors. Secondly we identified two sub-themes under the heading methods used to individualise treatments: methods used to make treatment decisions during the consultation, and methods to support patients after the consultation. Thirdly we identified

dissonance between the rhetoric of individualisation and doctors' clinical reports of how they had dealt with some of their patients.

### Understanding of individualised treatment

Doctors' understanding of individualisation ranged from evidence based medically focused, doctor-led care, through to prescribing drug treatments tailored to the patients' wishes and beliefs. There was variation in the ease with which doctors spoke about individualisation. There were two doctors who could not articulate their understanding of individualisation, but who were still able to respond to prompts about how they would deal with situations that could be considered to be amenable to individualisation. Whilst all but two doctors were able to describe their understanding of individualisation when asked, these answers did not always match the examples they provided.

Doctors frequently discussed individualisation in relation to two of the processes involved in the prescription and use of pharmacological treatment - selecting appropriate drugs to treat the individual patient, and the interaction with the patient in the medical consultation. Doctors paid less attention to patients' use of treatments post consultation.

#### *Evidence based medicine and doctor-led prescribing*

At one end of the spectrum, individualisation was considered to be synonymous with evidence based practice. Focussing on the doctors' task of selecting appropriate drugs to treat the individual patient, one doctor described how the process of matching patients with guidelines resulted in all treatments being individualised:

"I suppose when I did discuss it recently with my colleague the point he made was all treatments are individualised and it's, perhaps you're looking at it from a different perspective, because we look at it from the individual that comes in and then try and match a guideline to them or guidance, so everything you do is individualised anyway." (014Sophie, urban GP)

Importantly, when asked about their understanding of individualised treatment, no doctor referred to doctor-led prescribing specifically. However, it was implicit in their examples that in certain situations (i.e., such as if the doctor thought that the patient really could benefit from treatment), they considered a doctor-led style of prescribing to be individualised.

"Well again, it's a case of looking at what is right for that particular patient at that particular time, and, I, I, because the patient was at high risk of stroke, then I did really try to push the treatment." (004Jim, urban GP)

1  
2  
3 “You know, because I think if, somebody might be very against a drug, but if I’ve  
4 seen it work really effectively in the past, I suppose I feel, I wouldn’t force them to  
5 take it, if I force them to take it they won’t take it anyway, but I suppose I feel if I  
6 can find a way round it that would encourage them just to give it a go, sometimes  
7 it’s worth it.” (019Catherine, urban GP)  
8  
9

### 10 11 *Individualising treatments around patient factors*

12  
13 Doctors described individualised treatments as drug treatments that had been selected after  
14 consideration of patient factors (such as patient circumstances). Frequently, this meant adapting or  
15 going against guideline recommendations. Some doctors described individualised treatments as  
16 treatments that had been tailored to suit the patients’ medical needs (*for example, e.g.,* when  
17 treating patients with co-morbidities):  
18  
19

20  
21 “Well it’s always checking on individual preferences, but the biggest factor is co-  
22 morbidity, that’s what makes me step outside the box as it were.” (012Tom,  
23 *urban GP*)  
24  
25  
26

27 For other doctors, individualised treatments were treatments that had been adapted to  
28 suit patients’ social circumstances:  
29  
30

31 “So, I’ve got someone who lives out the back of beyond, no transport, they might  
32 be less keen to have something that requires frequent monitoring... We have a lot  
33 of shift workers round here so that can be quite an issue, um, shifts will often  
34 change from week to week... complete nightmare controlling anything like that  
35 because they’re sometimes asleep when they’re supposed to be taking their pills.  
36 So they can be tricky.” (017Rachel, rural GP)  
37  
38  
39  
40

41 For some, individualised treatment required the patient to be involved in treatment decisions; with  
42 treatments being individualised around *what the patients’ willingness to take a drug is prepared to*  
43 *do*. These doctors considered patients’ preferences to be more important than their own views and  
44 preferences. In particular, the two geriatricians in our sample were conscious that the patients’  
45 preferences are perhaps more important than achieving optimal control of their conditions:  
46  
47  
48  
49

50 “Because most of the patients that we see have reached what statistically would  
51 be regarded as their life expectancy. So there is, we can’t in anyway force our  
52 opinions on them. We have to go with the fact that they have made this value  
53 judgement as to what is the right thing for them... And we just have to accept that  
54 they’ve made the right judgement for them. Which is not necessarily the right  
55  
56  
57  
58  
59  
60

judgement for us. But as long as we feel that they are fully informed, or as informed as they can be, then we just accept what decisions they make on their behalf.” (001Mark, geriatrician)

“Maybe that’s easier in geriatrics where we know lots of what we do comes at a price, we know 10% of hospital admissions that we do are from drug side effects. So maybe we feel a bit more relaxed about it.” (013William, geriatrician)

For others, individualising treatment in accordance with ~~what~~ the patients’ willingness to take a drug ~~was prepared to do~~ simply meant accepting that the patient had declined treatment:

“And I’m quite happy to agree to differ, if they want to decline treatment, I’d write down declined treatment. I think it’s important to come back to, not just see it as something that they’ve done wrong, but it’s fine for them to do that, and I don’t have a problem with them not taking that treatment.” (006Marcus, urban GP)

### Methods used to individualise treatments

Doctors described the methods they used to achieve individualisation. Again, doctors focused on the methods used to select appropriate drugs to treat individuals and interactions with the patients during the consultation. Few doctors spoke of methods to support the patient to use treatments after the consultation when drug taking actually occurs.

#### *Methods used to make treatment decisions during the consultation*

Doctors described using a range of resources to select appropriate drugs to treat individual patients. These included evidence, clinical experience, colleague support, and the patients’ views or circumstance. Use of resources was dependent on doctors’ understanding of individualisation, but influenced by the patient and the situation. All doctors described using evidence to make treatment decisions. However, views about the role of the evidence varied between doctors:

“EBM is only one of many strategies, and, it’s like you’ve got a tool box you know? And the tool that you use every time is you yourself. And you need, and you can learn to do that better. I’m very interested in that. And then occasionally you’ll pull EBM out as well. But not, you know, not very often. Honestly, I would think I probably, as a first tool that you pull out, it would probably be once or twice a day.” (010Andrew, urban GP)

It was widely acknowledged that “text book” scenarios were rare. One general practitioner reported that most of his patients had complex social needs, and both the geriatricians in our sample reported that nearly all of their patients had multiple conditions. These complex patients could not

1  
2  
3 be treated only using evidence based guidelines<sup>(9)</sup>. Treatment decisions for patients with complex  
4 needs were made based on their own or their colleagues' clinical experience:  
5  
6

7 "Often we send messages to each other. I share a list with another GP colleague,  
8 and we share difficult patients, and discuss how are we going to get Mr so and so  
9 to do X, Y and Z?" (014Sophie, urban GP)  
10

11 To treat patients with complex needs, doctors often made treatment decisions for the patient, using  
12 strategies like polypharmacy to deal with side-effects of treatments, and accepting that not all  
13 conditions can be optimally managed:  
14  
15

16  
17 "Interviewer (I)Q: Ok, so when you've got a patient who comes in and has a range of medical  
18 conditions, and you know if you treat all of them it's going to lead to interactions?  
19

20  
21 "Respondent (R)A: The regimens for each of these conditions, A, B and C are reasonably well  
22 sorted because they're common conditions, common drugs, usually sorted. So he has  
23 arthritis, diabetes and epilepsy. That's a nice juicy mix, and fairly common. By and large you  
24 will get away with this polypharmacy." (008Mathew, urban GP)  
25  
26

27 To involve the patient in the treatment decisions, doctors reported using techniques such as  
28 providing the patient with the information needed to make an informed choice, suggesting  
29 treatment and outcome options, and giving the patient time to think about their priorities:  
30  
31

32  
33 "And then we can provide them with alternatives like 'well this will cure that but  
34 this could affect your kidneys. This might not have as big an effect on that but it  
35 would preserve the kidneys and could leave you a little bit short of breath. Of  
36 those two which would you rather have? The risk of feeling completely healthy,  
37 but potentially shorter life, or having some symptoms but a longer life?' And  
38 working with those decisions." (001Mark, geriatrician)  
39  
40  
41  
42

43 Whilst one doctor aimed to prescribe treatments in accordance with patients' interests, he  
44 accepted that this could not be an everyday occurrence:  
45  
46

47  
48 "I'll be honest; I don't do it all the time, so I don't want to pretend I'm perfect at  
49 this. I think the clearest one that I've got is a bloke in his late 50s with Parkinson's  
50 who'd retired, but the thing that kept him going was that he could go to the  
51 swimming pool every morning... So we opted for a patch for him... You slap it on  
52 once a day and it gives you 24 hour coverage so he could put it on the night  
53 before and he'd be switched on in the morning, he wasn't waiting for a tablet to  
54 kick in and make him work. And it worked beautifully for him... but after a few  
55  
56  
57  
58  
59  
60

1  
2  
3 months he got skin reactions and we had to stop it and find something else, but  
4 that really felt like we had really picked a drug around him and his interests and  
5 what was keeping him going." (013William, geriatrician)  
6  
7

8 Interviewees also reported situations in which a more directive approach was considered to  
9 be necessary. This included situations in which patients' goals were deemed unrealistic, or  
10 when the doctor thought that the patient really should be using some form of treatment.  
11 Doctors then reported using techniques in order to convince or persuade the patient to  
12 follow recommendations. In some cases, attempts were made to encourage the patient to  
13 see the medical imperative for treatment:  
14  
15  
16  
17

18 "They don't want to take any tablets; you say 'well you probably will die in 5 years time at  
19 the most without these things. If you take these things it might prolong your life, by this that  
20 or the other.'" (007Joe, urban GP)  
21  
22  
23

24 For some doctors, the assumption appeared to be that the patient was in some way misinformed.  
25 Therefore, attempts were made to educate the patient:  
26  
27

28 "Most of the time you can explain to people why they ought to be taking  
29 something and hopefully they might come round to thinking that that's the best  
30 thing to do. Sometimes people might have different ideas and won't take anything  
31 or certainly won't take what you suggest but I think most of the time you can  
32 explain to people why or what the evidence is or what the consensus is. And most  
33 of the time if people understand it they'll take it." (022Lynn, rural GP)  
34  
35  
36  
37

38 If initial treatment decisions were not acceptable to the patient, attempts were made to  
39 change or simplify the regime or to prescribe alternative treatments:  
40  
41

42 "You just say 'well let's try something else.' The nice thing is, there's always, or very  
43 often there's always alternatives that are either as good or, uh, you know, in the  
44 same league." (014Sophie, urban GP)  
45  
46

#### 47 *Methods used to support patients after the consultation*

48

49 In most interviews, individualisation was described in the context of making treatment  
50 decisions during the consultation. Few doctors spoke of methods to support patients to test  
51 and refine their treatment in the context of their own life. To support patients after the  
52 consultation, doctors reported using techniques such as reminders and instructions. This  
53 ranged from standardised dosette-monitored dosage system boxes or text messaging  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 services, to writings and drawings on prescription labels. Crucially, the aim of such  
4 strategies was to help the patient use their medications as prescribed:  
5

6  
7 “Q: Do you use any strategies to support the patients outside the consultation?  
8

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
RA: Um, not enough. It’s something I often think about that I should be doing  
more. So I do drawings and write things on bits of scrap paper, about if there is a  
complicated medication, or a list of things to do, or if people are older, forgetful”

(~~006~~ Marcus, urban GP)

A minority of doctors described using strategies to help patients modify treatment regimes  
to suit their lives. One geriatrician described how he used techniques such as separating  
drugs into those that have to be taken (to treat the condition) and those that do not have  
to be taken (to treat the symptoms):

“I tend to rearrange them so into treatments and symptoms... And if you group  
them like that, then if they get half way through the tablets, providing they’ve  
taken their treatment tablets, the symptom control, if they don’t take it they’re  
going to feel lousy, but the balance between taking a tablet or not taking a tablet,  
it’s not going to make any difference to their longer term health.” (~~001~~ Mark,  
geriatrician)

Another geriatrician described a process of trial and error, in which drugs were used for a  
period of time and then modified by the doctor if necessary:

“I think as well, because we tell patients for a lot of these drugs let’s try this and  
see if it works, if it’s not working we’ll stop it. It allows patients to come back and  
say it’s not working rather than come back and feel that they’re on it.”

(~~013~~ William, geriatrician)

Only one general practitioner actively encouraged patients to modify their treatments to  
achieve individualised doses. This doctor described reluctance on behalf of some patients  
to do so:

“So actually, for an awful lot of drugs, I do this all the time. I say balance up your,  
you know yourself when you’re getting the side effects. Titrate the medication until  
you’re just below the level at which you get the side effects and fiddle around with  
it... And then sometimes the patient’s say, ‘ohh, but it says once a day and bla bla  
bla.’” (~~007~~ Joe, urban GP)

1  
2  
3 The hospital consultants in our sample reported used diaries and graph paper to either  
4 assess the effectiveness of treatments and treatment doses, or to encourage patients to  
5 respond to worsening symptoms:  
6  
7

8 “So, it’s just a piece of paper really with days of the week and what their  
9 Parkinson’s is like. But Parkinson’s you swing from being on, when you can move  
10 around, to being off, when you’re frozen and stuck. So if we’re trying to give a drug  
11 to reduce the amount of time people are off, we’ll often give them a diary so you  
12 can graphically see whether it’s worked or not.” (013William, geriatrician)  
13  
14

15  
16  
17 “Well they all get the graph paper. And it’s “If it goes above this line, phone us and  
18 we’ll see you in clinic straight away. Or, if it goes above this line increase your  
19 tablets. Or do this that or the other.” And it’s what we tell them to do when it  
20 reaches that point that varies by patients.” (004Mark, geriatrician)  
21  
22

23  
24 The question of whether or not patients needed to be encouraged to monitor symptoms  
25 was contested. Some doctors were of the opinion that patients should not be encouraged  
26 to monitor their symptoms or side-effects of their treatments:  
27  
28

29 “I quite often don’t tell people about the side effects of tablets, which is against  
30 our, against all the modern day teachings that you must tell people of the risks.  
31 Well I often don’t. Because there’s a lot of evidence for this, there’s a type of  
32 patient that if you tell them there is a possibility that they’ll get headaches, they’ll  
33 get headaches.” (002John, clinical academic)  
34  
35  
36

37  
38 Others felt that patients should be told what potential side effects they should look out for:  
39

40 “Explain to them the possibility that one thing might affect another and what to  
41 look out for. So if there are going to be interactions, what they, what they need to  
42 be um, coming back with um, if certain symptoms present. You know if you get this,  
43 come back, because that’s a side effect we need to know about.” (016Becky, urban  
44 GP)  
45  
46  
47

48  
49 However, even with clear instructions, mistakes could happen:  
50

51 “We’ve had that with a patient who used, you know, he had the line [indicating safe  
52 blood pressure readings], he went way below the line, kept on going without  
53 bothering to phone anyone, and six weeks later he was in hospital with renal  
54 failure. And we gave him pretty clear instructions. He decided to ignore them... It  
55  
56  
57  
58  
59  
60



worked; he just didn't follow the instructions. But you can't do anything about that.

Patients are entitled to do what they want." (001Mark, geriatrician)

There was wide acceptance that, in the end, the final treatment decision was down to the patient. In certain situations, no treatment could be the best option:

"You know, you say, 'this is what's going on, you tried them we've looked at physiotherapy, we've looked at other alternatives, are your symptoms manageable? Are the treatments worse than the condition, and if they are, then maybe you need to learn to live with the condition.'" (017Rachel, rural GP)

### **Dissonance between rhetoric and experience**

Whilst all but two doctors were able to describe their understanding of individualisation when asked, these answers did not always match the examples they provided when talking about patients they had treated. For example, one doctor described individualisation as being:

"All sorts of things. Everything from the persons' views or thoughts about - if you're talking about medicines - about drugs and what they want. But similarly that fits with their views of whether they like medicine, don't like medicine, what they want in terms of getting better." (Catherine, urban GP).

However, when this participant was asked how she would respond to a patient who did not want to use the treatment that she had prescribed, she responded:

"There are even times when I'll say 'well actually I think this would be worth trying' even if they're not very keen. And I'll say to them 'how about you give it a go for two weeks and see how you feel.' You know, because I think somebody might be very against a drug, but if I've seen it work really effectively in the past, I suppose I feel, I wouldn't force them to take it, if I force them to take it they won't take it anyway, but I suppose I feel if I can find a way round it that would encourage them just to give it a go, sometimes it's worth it" (Catherine, urban GP).

This dissonance between rhetoric and experience was evident throughout the interviews. Whilst doctors appeared to think that individualising treatments around patients' preferences and world views into treatment decisions was of value, in practice this was not always considered to be the best strategy.

## **DISCUSSION**

### **Main findings and comparisons with other studies**

1  
2  
3 This paper presents a range of doctors' understandings of the meaning of individualised drug  
4 treatment. ~~Overall, there was a lack of consensus about whether i~~individualised treatment was  
5 ~~discussed in relation to both~~ treatment that was tailored to patients' priorities, and treatment that  
6 was doctor-led and followed evidence based guidelines. Furthermore, there was a lack of  
7 congruence between doctors' stated definition of individualisation and the examples they provided  
8 ~~from their practice~~. Doctors frequently spoke of methods to support interactions during  
9 consultations, the first of the processes referred to in the introduction of this paper. However,  
10 despite the findings of Pound et al<sup>(21)</sup>, doctors in our study infrequently mentioned patients' use of  
11 their medications outside the consultations.

12  
13 The main strength of this study is the use of qualitative methods to generate a rich insight into  
14 doctors' understanding of individualisation, methods used to achieve individualisation, and the  
15 relationships between the two. We used strategies to enhance the trustworthiness of our study,  
16 including multiple coders and respondent validation. We triangulated our findings with the existing  
17 literature, and asked participants to comment on our findings<sup>(28)</sup>. Participants who took part in pilot  
18 interviews stated that they could recognise our findings, and agreed that they were plausible.

19  
20 Our study was based on a sample of hospital consultants and general practitioners from the South  
21 West of England. That doctors were only recruited from this area could limit the transferability of  
22 the results, although participants had both trained and practised beyond this region. ~~Whilst we~~  
23 ~~report that the four hospital consultants appeared to be more willing than general practitioners to~~  
24 ~~individualise treatments after the consultation, this is based on a small number of participants.~~  
25 ~~Further research is needed to explore differences in individualisation between different clinical~~  
26 ~~specialities. This may highlight situations clinical areas in which individualisation is commonly~~  
27 ~~achieved and situations in which individualisation is not so appropriate.~~ We acknowledge that our  
28 use of opportunity sampling may have resulted in a self-selected sample. ~~However, our results~~  
29 ~~demonstrate the lack of consensus about what individualisation of drug treatments means to~~  
30 ~~participating doctors, suggesting that there is no shared understanding of what the term means. The~~  
31 ~~lack of consistency between respondents' definitions of individualisation and the examples they~~  
32 ~~gave suggests that there may also be inconsistency between their explanations and their clinical~~  
33 ~~practice. However, as we are interested in best practice, we were not overly concerned with~~  
34 recruiting only those with an interest in the study.

35  
36 Previous qualitative research has explored methods to support doctors during consultations<sup>(16-18)</sup>. In  
37 those studies, the focus was on strategies used by doctors to make individualised prescribing  
38 decisions within the medical consultation - where guidelines may not be appropriate. Similar to the  
39 doctors in our study, those studied in the study by Fried et al. had variable views about how  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 treatment decisions for patients with complex conditions should be made. Use of evidence and  
4 strategies to balance the harms versus the benefits of guideline directed care varied between  
5  
6 physicians.

7  
8 Doctors in both [of these](#) studies had differences of opinion regarding the role of the patient in  
9 treatment decisions. For some, treatment decisions should be doctor-led, with the doctor  
10 persuading the patient to use the treatment that they thought would be most appropriate. For  
11 others, patient involvement was an essential component of treatment decisions. A number of  
12 doctors reported that integrating patients' preferences into medical decisions was problematic if the  
13 treatment was essential. This was still a major concern for many doctors, despite research  
14 suggesting that patients' and doctors' priorities may be very different<sup>(29)</sup>. [This paternalism versus  
15 patient choice is an ongoing debate, and one that is widely discussed in the literature<sup>\(15;30;31\)</sup>. In the  
16 current paper, the dissonance between the rhetoric of individualisation and doctors' clinical  
17 behaviour appeared to stem from this issue, with the data revealing tensions between doctors  
18 desire to treat the patients' social needs, whilst simultaneously treating their medical needs.](#)

19  
20 Pound et al found evidence to suggest that patients actively modify their medications in order to suit  
21 their lives<sup>(21)</sup>. However, there is a paucity of literature surrounding methods used to support  
22 patients during this third process. The few doctors in our study who spoke of methods to support  
23 patients outside the consultation described methods such as sorting drugs by their role (to treat or  
24 to cure), trial and error, and monitoring. These strategies are largely informal: [for example,](#)  
25 drawings, or writing about the use of the medication on bits of paper. The limitations of such  
26 informal methods were acknowledged.

27  
28 [The lack of consideration of what goes on outside the consultation is particularly interesting and  
29 worrying. Pound et al., \(2005\) has shown that many patients will monitor their symptoms and side  
30 effects and make treatment adaptations as necessary – with or without the support of the doctor.  
31 Self-management of chronic disease requires patients to take multiple treatments and monitor their  
32 health over many years. Therefore, strategies to support patients to modify treatments, and  
33 providing safe parameters for them to do so, may actually limit patient driven amendments to  
34 treatments without professional support. However,](#) our study highlights the variation in opinions  
35 about whether or not patients should be encouraged to adapt treatments after consultations. One  
36 doctor felt that patients did not want to adapt their treatments. Another doctor thought that  
37 encouraging patients to be aware of side-effects could actually contribute to side effects. Others  
38 were concerned that encouraging patients to monitor symptoms could lead to unnecessary stress.  
39  
40 Only a small number of doctors ([mainly from secondary care](#)) thought that patients should be  
41 encouraged to individualise treatments after the consultation. [In particular, the two geriatricians](#)

seemed to have a better understanding of, and a larger set of methods to support patients to individualise treatments after consultations than the general practitioners, thus suggesting that the findings might be related to medical subspecialty. Further research is needed to explore differences in individualisation between different clinical specialities, as this may highlight situations clinical areas in which individualisation is commonly achieved, and situations in which individualisation is not so appropriate. However, as Pound et al., (2005) has shown, many patients will monitor their symptoms and side effects and make treatment adaptations as necessary—with or without the support of the doctor. Self-management of chronic disease requires patients to take multiple treatments and monitor their health over many years. Developing tools to support patients to modify treatments, and providing safe parameters for them to do so, may actually limit dangerous adaptations.

The findings reported here have important implications for research and practice. The focus of ~~the doctors in~~ this study was on the strategies and methods that ~~doctors doctorsthey~~ used to reach decisions within the consultation. Few doctors discussed methods to support patients to use drug treatments outside the consultation. Methods that were suggested were informal and unstructured, and doctors acknowledged that such methods may neither be supportive enough or measurable. Furthermore, doctors perceived a number of barriers to individualising treatments after the consultation; such as whether or not strategies could contribute to side-effects and cause unnecessary stress. Before policy recommendations concerning both individualisation and self-management can be achieved commissioners need to be clear about what they are advocating, thus, the concept of individualisation needs to be refined. Methods used to achieve individualisation may then be developed and piloted in different situations. Such methods should be appropriately structured to be supportive and their effects measurable. Given that some patients are already individualising treatments on their own, supporting patients to do so safely could improve patients' self-management practices.

### **Acknowledgements**

We would like to thank the participants who took part in the research.

### **Competing interests**

All authors have completed the ICMJE uniform disclosure at [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) (available on request from the corresponding author) and declare: SD's time is funded by NIHR; no financial relationships with any organizations that might have an interest in the submitted work in

1  
2  
3 the previous three years; no other relationships or activities that could appear to have influenced  
4 this work.  
5

### 6 7 **Funding**

8  
9 This article presents independent research funded by the National Institute for Health Research  
10 (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for the South  
11 West Peninsula. The views expressed in this publication are those of the author(s) and not  
12 necessarily those of the NHS, the NIHR or the Department of Health in England  
13  
14

### 15 16 **Copyright**

17  
18 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of  
19 all authors, a worldwide license to the Publishers and its licensees in perpetuity, in all forms, formats  
20 and media (whether known now or created in the future), to i) publish, reproduce, distribute, display  
21 and store the Contribution, ii) translate the Contribution into other languages, create adaptations,  
22 reprints, include within collections and create summaries, extracts and/or, abstracts of the  
23 Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all  
24 subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to  
25 third party material where-ever it may be located; and, vi) license any third party to do any or all of  
26 the above.  
27  
28  
29  
30  
31  
32

### 33 34 **Contributions and guarantor**

35 All four authors had a substantial contribution to the conception and design of the research. The  
36 analysis and interpretation of the data was undertaken by Sarah Denford, with considerable input  
37 from Julia Frost, Nicky Britten and Paul Dieppe. The article was drafted by Sarah Denford, and  
38 revised by the remaining three authors. All four authors approved the final version of the article  
39 before publication. There were no other contributors that are not included as an author. Sarah  
40 Denford is the guarantor.  
41  
42  
43  
44

### 45 46 **Data sharing**

47 Full dataset is available from the corresponding author at Sarah.denford@pms.ac.uk. Consent was  
48 not obtained but the presented data are anonymised and risk of identification is low.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCE LIST

- 1  
2  
3  
4  
5 (1) Department of Health. Equity and excellence: Liberating the NHS. Stationary Office, 2010.
- 6  
7 (2) Department of Health. Supporting people with long term conditions. Stationary Office,  
8 2005.
- 9  
10 (3) Cribb A, Owens J. Whatever suits you: unpicking personalization for the NHS. *J Eval Clin Pract*  
11 2010;16(2):310-4.
- 12  
13 (4) Haynes RB, Sackett DL, Gray JM, Cook DJ, Guyatt GH. Transferring evidence from research  
14 into practice: 1. The role of clinical care research evidence in clinical decisions. *ACP J Club*  
15 1996 Nov;125(3):A14-A16.
- 16  
17 (5) Hayward RS, Wilson MC, Tunis SR, Bass EB, Guyatt G. Users' guides to the medical literature.  
18 VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The  
19 Evidence-Based Medicine Working Group. *JAMA* 1995 Aug 16;274(7):570-4.
- 20  
21 (6) Evans I, Thornton H, Chalmers I, et al. Testing treatments better research for better  
22 healthcare. London: Pinter & Martin, 2010.
- 23  
24 (7) Kravitz RL, Duan N, Braslow J. Evidence-Based Medicine, Heterogeneity of Treatment Effects,  
25 and the Trouble with Averages. *Mil Quart* 2004;82(4):661-87.
- 26  
27 (8) Mant D. Can randomised trials inform clinical decisions about individual patients? *Lancet*  
28 1999;353(9154):743-6.
- 29  
30 (9) Boyd CM, Darer J, Boulton C, et al. Clinical Practice Guidelines and Quality of Care for Older  
31 Patients With Multiple Comorbid Diseases. *JAMA* 2010;294(6):716-24.
- 32  
33 (10) Lewin S, Skea Z, Entwistle VA, et al. Interventions for providers to promote a patient-  
34 centred approach in clinical consultations (Cochrane review). *Cochrane Libr* 2012;  
35 2001;(4):CD003267.
- 36  
37 (11) Marshall M, Bibby J. Supporting patients to make the best decisions. *BMJ* 2011;342:d2117.
- 38  
39 (12) Agedahl KM, Gulbrandsen P, Forde R, et al. Courteous but not curious: how doctors'  
40 politeness masks their existential neglect. A qualitative study of video-recorded patient  
41 consultations. *J Med Ethics* 2011;(24)107-113.
- 42  
43 (13) Richards N, Coulter A. Is the NHS Becoming more Patient-centred? Trends from the National  
44 Surveys of NHS Patients in England 2002-07. London: Picker Institute; 2007.
- 45  
46 (14) Cribb A, Entwistle VA. Shared decision making: trade-offs between narrower and broader  
47 conceptions. *Health Expect* 2011;14(2):210-9.
- 48  
49 (15) Sandman L, Munthe C. Shared decision making, paternalism and patient choice. *Health Care*  
50 *Anal* 2010;18(1):60-84.
- 51  
52 (16) Anderson N, Fuller R, Dudley N. 'Rules of thumb' or reflective practice? Understanding senior  
53 physicians' decision-making about anti-thrombotic usage in atrial fibrillation. *QJM*  
54 2007;100(5):263-9.
- 55  
56  
57  
58  
59  
60

- 1  
2  
3 (17) Fried T, Tinetti ME, Iannone L. Primary Care Clinicians' Experiences With Treatment Decision  
4 Making for Older Persons With Multiple Conditions. *Arch Intern Med* 2011;171(1):75-80.  
5  
6 (18) Luijckx HD, Loeffen MJ, Lagro-Janssen AL, et al. GPs' considerations in multimorbidity  
7 management: a qualitative study. *Br J Gen Pract* 2012;62:e503-e510.  
8  
9 (19) Schattner A, Fletcher RH. Research evidence and the individual patient. *QJM* 2003;96(1):1-5.  
10  
11 (20) Griffiths F, Green E, Tsouroufli M. The nature of medical evidence and its inherent  
12 uncertainty for the clinical consultation: qualitative study. *BMJ* 2005;330(7490):511.  
13  
14 (21) Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of  
15 medicine taking. *Soc Sci Med* 2005;61(1):133-55.  
16  
17 (22) Britten N. Qualitative interviews in medical research. *BMJ* 1995;311(6999):251-3.  
18  
19 (23) Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;(2):77-101.  
20  
21 (24) Miles MB, Huberman AM. *Qualitative data analysis: an expanded sourcebook*. 2nd ed.  
22 Thousand Oaks: Sage Publications; 1994  
23  
24 (25) Shenton AK. Strategies for Ensuring Trustworthiness in Qualitative Research Projects. *Educ*  
25 *for Infor* 2004;(12):2-63.  
26  
27 (26) Mays N, Pope C. Rigour and Qualitative Research. *BMJ* 1995;(6997):109-12.  
28  
29 (27) Ritchie J, Spencer L, O'Connor W. Carrying out Qualitative Analysis. In: Ritchie J, Lewis J,  
30 editors. *Qualitative Research Practice*. 1st ed. London: SAGE; 2003. p. 219-63.  
31  
32 (28) Lincoln YS, Guba EG. But is it rigorous? Trustworthiness and authenticity in naturalistic  
33 evaluation. *New Directions for Program Evaluation* 2004;(30):73-84.  
34  
35 (29) Britten N. Commentary: Does a prescribed treatment match a patient's priorities? *BMJ*  
36 2003;(7419):840.  
37  
38 (30) Coulter A. Paternalism or partnership? *BMJ* 1999; (7212):719-20.  
39  
40 (31) Upton J, Fletcher M, Madoc-Sutton H, Sheikh A, Caress AL, Walker S. Shared decision making  
41 or paternalism in nursing consultations? A qualitative study of primary care asthma nurses'  
42 views on sharing decisions with patients regarding inhaler device selection. *Health*  
43 *Expectations* 2011;  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60